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Abstract

The Role of the Microbiome in Regulating House Dust Mite-Induced Asthma
Alexander John Adami, PhD
University of Connecticut, 2018

Asthma is a complex and highly heterogeneous disease characterized by inflammation of the
airways, leading to a host of respiratory symptoms including wheeze and dyspnea. Asthma is the
product of multiple interconnected immunological processes and represents a constellation of
related, but distinct, disease phenotypes. Disturbingly, the prevalence of the disease has more
than doubled since the 1980s, and efforts to understand this increase have led to the
consideration of the microbiome, or the communities of microorganisms that dwell on and within
us, as a key player in the pathology and regulation of this disease. While recent years have seen
an explosion of new research in this area, we are only beginning to untangle to mechanisms by
which the microbiome may influence asthma. Utilizing a house dust mite-induced model of
experimental asthma, we explored the relationship between the microbiome and the development
of both allergic airway disease and the development of tolerance and disease resolution. Herein,
we report that HDM exposure has can alter the gut microbiome, producing distinct changes in the
microbial community over the course of HDM exposure, but that these effects are not consistent
between treatment groups. We demonstrate that oral tolerance is not inducible for HDM, in
contrast to a large body of evidence in other experimental allergens such as ovalbumin,
suggesting that the inhalational tolerance seen with this allergen forms by independent

Alexander John Adami - University of Connecticut, 2018
mechanisms within the lungs. We describe a new, clinically-relevant model of early-life antibiotic
exposure that produces heightened asthma severity, including the first evidence that brief
exposure to antibiotics after weaning is sufficient to alter the pathophysiology of asthma later in
life. Furthermore, we demonstrate that the enhanced disease seen in this model may arise from
deficiencies in pulmonary regulatory T Cells driven by loss of diversity in the microbiome. Finally,
we explore the ability of antibiotic treatment to influence the development of inhalational tolerance,
reporting that lifelong exposure to antibiotics can impair tolerance development through
mechanisms that may be mediated by a loss of regulatory T and B Cells.
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CHAPTER 1
INTRODUCTION
What is Asthma?
The term “asthma” conjures many images. To the public, it represents inhalers, wheezing, and
difficulty breathing. Physicians think of corticosteroids, bronchodilators, and the patients they
care for in the throes of asthma attacks. An immunologist sees the immunopathology and
immunological forces behind the disease, such as eosinophils or inflammatory cytokines. Asthma
is all these things and many more besides, and untangling the complexity of the disease has
challenged medical science since the dawn of the profession[1].
At its heart, asthma is a disease of dysregulated immune responses resulting in chronic
inflammation of the airways[2]. This inflammation promotes thickening of the airway wall, primarily
due to fibrotic remodeling and airway smooth muscle (ASM) hypertrophy and hyperplasia[3]. The
thickened wall is augmented by goblet cell hyperplasia and increased production of mucus[4].
This increased mucus, and the need to remove it, is one factor behind the cough seen in many
suffering from the disease[4], and together with thickening of the ASM it reduces the crosssectional area of the airway lumen significantly, restricting airflow. Spasm and hyper-reactivity of
the thickened ASM layer further constrict the lumen and impede airflow[2]. For asthmatics, this
process is what produces the wheeze, chest tightness, and dyspnea that are responsible for much
of the suffering of the condition. In the early stages of asthma, this constrictive, obstructive
process is characteristically reversible with bronchodilators, but after many years of asthmatic
inflammation and remodeling, the obstruction can become irreversible and constant[5].
Asthma may fundamentally be a disease of airway inflammation, but this inflammation can
manifest itself in multiple ways. While commonly thought of as a disease of childhood, asthma
may appear throughout life[6]. The severity of symptoms, frequency of severe asthma attacks (a
2

sudden worsening of asthma symptoms), and response to treatment vary between and within age
groups[4]. Some children who acquire asthma grow out of it, while others seem unable to shake
the condition[7]. Indeed, the heterogeneity of the disease may explain why the most effective
therapies we have are broadly immunosuppressive (inhaled or systemic corticosteroids), act on
ASM to dilate the airway and restore airflow (bronchodilators), or perform a combination of the
two actions (leukotriene antagonists)[4].
The recognition of asthma’s heterogeneous presentation prompted a reconsideration of the very
nature of the disease. Long deemed a (if not the) prototypical T Helper Type 2 (Th2)-mediated
disease, subsets of asthma that display few or no characteristics of Th2 inflammation are today
well-recognized[8]. The concept of asthma is now one of multiple phenotypes, each with distinct
features and immunological processes[8–10]. This new understanding has led to some, such as
the editors of The Lancet, to call for the abandonment of asthma as a single disease concept[1].
One asthma researcher, Fernando Martinez, has likened the modern concept of asthma to fever,
which was considered a disease unto itself until the 1800s[11]. No modern physician would
describe fever as a disease, for we understand that fever can arise from a host of distinct
processes. In the coming years and decades, we may realize the same to be true for asthma.

The Actors on Asthma’s Immunologic Stage
As complex as asthma’s presentation can be, the cast of immunologic actors that put on the
asthma “show” is more complex still[8; 9]. Consider the classic picture of allergic asthma, that of
a Th2-driven response against an innocuous environmental antigen, characterized by
eosinophilia, airway hyper-reactivity (AHR), and abundant production of IgE[2]. CD4+ T cells
reside at the center of this process, directly or indirectly providing cytokines and chemokines to
promote the development of eosinophils, expansion of goblet cells, and development of AHR[8;
9]. Despite this seemingly complete picture, new discoveries are constantly expanding on the
details regarding the players participating in the Th2 response. To pick just one recent example,
3

a subset of interleukin (IL) 21-producing CD4+ T cells was shown to be capable of modulating
Th2 responses in mice, and the loss of these cells led to reduced airway inflammation in an
experimental asthma model[12].
Intriguingly, CD4+ T cells are not the only orchestrators of Th2 immunity, and a recently-described
player of increasing importance is the innate lymphoid cell, type 2 (ILC2). ILC2s are members of
a group of cells collectively dubbed innate lymphoid cells (ILCs) that straddle the fence between
adaptive and innate immunity, exhibiting many of the activities of T cells without the
accompanying T cell receptor or clonal expansion in response to antigen[13].

Multiple

experimental models have described ILC2s, in particular, as critical mediators for the induction of
Th2 responses. While some of the earliest evidence of ILC2 participation in Th2 responses was
in the context of parasite expulsion[14] (n.b. “nuocytes” refers to ILC2s in this and other papers),
a growing body of work links ILC2s to the mediation of Th2 responses in experimental asthma[15–
18]. Their importance is such that loss of these cells provides resistance to asthma development
in mice[16–18]. While many of the details of ILC2 mediation of Th2 responses remain to be
determined, we know that they are capable of producing many of the same cytokines of a classic
Th2 response, including IL-4, IL-5, and IL-13[16; 17], and that they promote the migration of
dendritic cells (DCs), a class of professional antigen-presenting cells, to lung-draining lymph
nodes to present allergen to T cells[16; 18]. The latter is of such importance that Th2 memory
responses are impaired in the absence of ILC2 activity[18]. Perhaps most interestingly, ILC2s
can induce robust Th2 responses even in the absence of the adaptive immune system
(particularly CD4+ T cells)[15], suggesting that these cells alone may be capable of driving asthma
pathogenesis. Unfortunately, while our knowledge of how ILC2s orchestrate asthma in the mouse
is growing, the challenges of studying specific immune pathways in humans mean that relatively
little is known about the role of ILC2s, or ILCs in general, in the development of human asthma[13;
19].
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One particularly interesting development in asthma pathogenesis has been the realization that
pathways outside the traditional Th2 axis can drive asthmatic responses, particularly in adultonset disease[8; 9]. In these subjects, and experimental animal models mimicking their disease,
neutrophils dominate the inflammatory infiltrate, with eosinophilia and other characteristics of Th2
immunity being seemingly absent. Experimental work in animal models of asthma has pointed to
the involvement of Th17 cells, a subset of helper T cells known for production of IL-17. Both Th17
cells and the IL-17 they produce have been linked to the recruitment of neutrophils to airways[20],
increased severity of airway inflammation[21], and the promotion of AHR[22]. In humans, airway
neutrophilia negatively correlates with airway function[23], and asthmatic airways on the whole
tended to have more Th17 cells than controls[24]. Intriguingly, Th17 cells in animal models have
been shown to be resistant to steroid therapy[21], and human Th17 cells seem to share this
property[25], potentially explaining why human adults with severe asthma are often resistant to
steroid treatment[26]. However, work in this area is far from complete, and many questions
remain. For example, one early study of IL-17 in allergic asthma showed a protective effect
against allergic inflammation[27], likely due to replacement of Th2 activity (and corresponding
allergic disease parameters like eosinophilia) with Th17-driven activity. As suggested in this
study, the effect of Th17 immunity may depend on when in the disease process it is roused. Given
the difficulty of treating individuals with the most severe forms of asthma, further study of the role
of Th17 immunity in asthma is desperately needed.
Thus far, the discussion has focused on pro-inflammatory immune mechanisms, but regulation of
immunity is of equal, and if not greater, importance to asthma and to efforts aimed at treating the
disease. Asthma can be thought of as an imbalance between regulation and inflammation, with
too much inflammation and too little regulation. One of the most studied regulatory cell types is
the regulatory T cell (Treg), a class of T lymphocytes first identified as being protective against
autoimmune inflammation[28]. Since the initial identification of these cells, the role of Tregs in
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regulating inflammation, including that seen in asthma, has only grown[29]. Treg expression of
transforming growth factor β (TGF-β) has been shown to mediate tolerance, or lack of immune
response, to inhaled allergens[30], and several studies have shown that the suppression of
experimental asthma is accompanied by accumulation of Tregs in the lung and lung-draining
lymph node[31; 32]. Tregs have been shown to protect against experimental asthma by reducing
the activity of DCs[33] as well as suppressing Th17 cells and production of IL-17[34]. Finally,
inducible Tregs (iTregs), or Tregs which form in peripheral tissues rather than in the thymus,
protect against Th2 inflammation in both the gut and lungs[35].
Importantly, there is strong evidence to suggest that Tregs play an important role in the regulation
of human asthma. Human Tregs treated with steroids are able to upregulate production of the
anti-inflammatory cytokine IL-10[36], hinting at one potential mechanism for the efficacy of this
class of drugs. Tregs have been shown to be reduced in the blood of asthmatic individuals relative
to control subjects and also possessed diminished suppressive capability[37]. Interestingly,
comparisons of Treg numbers in the lungs of asthmatic and non-asthmatic individuals (using
broncho-alveolar lavage, or BAL, to assess airway cell populations) have been mixed. One study
demonstrated that airway Tregs are diminished in asthmatic adults[24], and a pediatric study
reported these Tregs to be functionally impaired in asthmatic children [38]. However, earlier work
in adult asthmatics reported increased numbers of Tregs in asthmatic airways[39], although they
did not examine Treg function. One possible explanation is that these studies assessed patients
broadly classified as having “asthma” but who may have exhibited subtly different asthma
phenotypes.

More study, particularly comparing human Treg populations between asthma

classifications, is required.
Tregs are not the only regulators of asthma pathology, a perhaps unsurprising revelation given
the numerous effector cell types seen in asthma. Among these additional regulators are a subpopulation of B cells, the precursors of the antibody-producing plasma cells, known as regulatory
6

B cells (Bregs)[40]. Bregs have been linked to suppression of inflammation in a number of
disease states, often through interaction with Tregs[41], and evidence for their suppressive ability
in asthma is increasing.

Bregs have been found to suppress symptoms of experimental

asthma[42] and later work linked this suppression to induction of Tregs[43]. Bregs may exert their
regulatory powers in the lung-draining lymph node, where they have been shown to accumulate
during the stage of tolerance development[41]. Unfortunately, evidence of a role for Bregs in
human asthma is relatively limited. One recent investigation reported that B cells from asthmatic
patients produced less IL-10 than those from controls, suggesting that a qualitative difference in
Bregs may exist in human asthma[44].
A further cell type with regulatory activity is the DC. A subset of DCs has been shown to be
protective in animal models of asthma[45]. Subsequent studies have extended this finding and
reported that disease protection is mediated through DC induction of Tregs[46], that proteolytic
modification of DC surface markers can reduce asthma pathology[47], and that one subset of
regulatory DCs critical for asthma protection is characterized by surface expression of CD103[48].
Interestingly, at least one human study of asthmatics has reported CD103+ cells in the vicinity of
sites of inflammation in the lung[39], although they appeared to be T cells rather than DCs and
their exact function was not assessed. However, the DC-asthma story is complex, and there is
equally good evidence that subsets of DCs help promote Th2 inflammation[49]. Which role DCs
play may depend on their interactions with other immune cell types, including ILCs[13] and
Tregs[33].

Asthma: A Growing Epidemic
Asthma has been a scourge of humanity since ancient times, but in the latter half of the 20th
century asthma prevalence took a sharp turn upwards. Representing what one group dubbed the
“asthma epidemic”[50], rates of childhood asthma more than doubled, rising from under 4% prior
to the 1980s to a peak of nearly 10% by 2009[50–54]. While there is some recent evidence that
7

overall prevalence may be stabilizing, certain populations, including poor children, adolescents,
and those dwelling in the Southern United States, continue to experience rising rates of
asthma[54].

The numbers of affected children continues to rise, with a 20% increase in

prevalence over the span of a decade[53].
However, one important point to consider with respect to asthma prevalence studies is that the
heterogeneity of asthma presentation and lack of a gold-standard diagnostic test for the disease
have long made estimates of asthma prevalence challenging for epidemiologists[10; 50]. To what
degree prevalence numbers are an overestimate (or an underestimate) remains uncertain, but
that they are imprecise is a certainty.

For example, some types of asthma that are not

accompanied by a Th2 response may be missed by surveys that utilize IgE and pinprick testing
as key components of diagnosis.
Regardless of whether prevalence continues to rise or has stabilized, asthma continues to
produce millions of missed school and work days[52], representing a significant drain on the
national economy and a hindrance to learning. Even more troubling, asthma remains the third
leading cause of hospitalization in children, behind only accidents and pneumonia[55], a costly
burden both to children and the larger healthcare system. From a health disparities perspective,
asthma is challenging disease for many minority populations in the United States.

African

American children have higher prevalence of asthma, approaching 15% compared to under 9%
for other groups, a disparity that has worsened significantly since the 1980s[54]. US children of
Puerto Rican descent fare event worse; for them, asthma prevalence has risen every year since
2001, and in 2015 asthma prevalence lay between 15 and 20%, the highest of any group[54].
Unfortunately, efforts to staunch the rising tide of asthma are hampered by an understanding of
how to prevent asthma that remains minimal at best[52]. Until we can uncover the etiology (or,
more likely, etiologies) of asthma, the best we may hope for is stabilization and not increase.

8

Cleaner Is Not Always Better: the Hygiene Hypothesis
In the decades since the upward trend in asthma prevalence first became apparent, many
theories have been advanced to explain the rise. Among the most compelling, and the most
supported by epidemiological evidence, is the hygiene hypothesis. Originally raised in a study of
hay fever by Strachan[56], the hygiene hypothesis states that the increasingly clean and sterile
environment of modern man has promoted the development of many diseases, including asthma.
In the quarter-century since Strachan’s proposal, evidence in support of his hypothesis has gone
from a few observations to a host of epidemiological studies[57] and, in some instances,
interventions.
What, though, is the common thread? Interestingly the answer may have been proposed over 20
years prior to Strachan’s hygiene hypothesis paper. In the 1970s, a Canadian team comparing
native communities with white communities made the observation that native communities
suffered far less from asthma and allergic disease than their white counterparts. Far ahead of
their time, the researchers opined that the higher frequency of asthma and allergy was merely
“the price paid by some members of the white community for their relative freedom from diseases
due to viruses, bacteria and helminths”[58]. Microbes, or lack thereof, could be the source of the
asthma epidemic[59].

Bring on the Bugs: the Microbiome
The term “microbiome” was popularized by Joshua Lederberg in the beginning of this century[60],
refers to the microorganisms that inhabit our bodies and their interactions with the environment in
which they live, namely us (for a discussion of the term microbiome and its conflicting definition,
refer to Box 1). While the science of the microbiome has soared primarily in the last two decades,
the idea that we possess microbiomes and that they can impact our health is far from new.
Escherich’s description of bacteria from the infant digestive tract is perhaps the earliest mention
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of microorganisms living within humans[61], and his observations were soon followed by those of
Döderlein[62] for the vaginal microbiome. A more remarkable concept is the idea that we may be
able to harness our knowledge of the microbiome in order to promote healthier and longer lives,
a concept Metchnikoff first proposed over a century ago[63].
However, while recognition of the existence and some of the effects of the microbiome on human
health is not new, it took the advent of next-generation sequencing (NGS) techniques to
meaningfully advance the study of the specific mechanisms of human-micobiome interactions.
Methods to culture some organisms (E. coli, K. pneumoniae, S. aureus, etc) have long been
known, but as many as a quarter of organisms present in the human gut may be unculturable[64].
This may be an underestimation; for soil, it is estimated that over 99% of all bacterial species are
not able to be cultured with modern techniques[65]. NGS changed the equation, removing the
need to culture and allowing a broader group of scientists, even those without expertise in
microbial culture and identification, to analyze the entire microbiome and its constituents[66].
Today, efforts to uncover the secrets of the microbiome are influencing every field of medical
science, from neuroscience[67] to metabolism[68–70] and beyond.

Broad, interdisciplinary

studies led by the governments of the United States[71; 72] and Europe[73] go further still, and
seek to not simply determine which microorganisms are part of the microbiome but what they are
doing and what they are making.
The explosion in science and knowledge related to the microbiome has revealed many exciting
new possibilities for advancing human health, but it has also revealed a disturbing trend. Humans
have likely coexisted with our microbiome since before we were a species. However, as we have
shaped our environment into one that is increasingly clean and sterile, we have fewer
opportunities to acquire or be exposed to microorganisms. Put another way, our increasingly
hygienic world has led to the loss of many so-called microbial friends[74]. Dubbed the “old friends”
hypothesis[75], this addition to the hygiene hypothesis predicts that it is the loss of exposure to
10

microorganisms, many of whom we co-evolved with, that lies behind increases of many diseases
of the modern age, from diabetes and obesity to allergy and asthma.

The Benefits of Dirty Living
The idea that microbial exposure can protect against asthma has a long history of clinical evidence
to support it. In addition to the aforementioned comparison of native and white communities in
Canada[58], two large studies took advantage of natural human experiments in Germany and
Karelia. Prior to reunification, East and West Germans shared common heritage and culture but
had decidedly different living situations. Examining the risk of asthma between the two states, a
pioneering team reported that the West Germans, despite their “advanced” economy and better
living conditions, suffered higher rates of asthma than the East[76]. The group hypothesized that
this difference may have arisen from the East German tendency to place their children in day care
from an early age while mothers went to work[76], a hypothesis which has been validated
since[77]. Karelia, a region of southeastern Finland and northwestern Russia, has a common
culture but has long been divided by the Finnish-Russian (formerly Finnish-Soviet) border. In
Russian Karelia, the population is poorer, lives in less clean environments, and has lower rates
of asthma compared to Finnish Karelians[78]. Intriguingly, those in Finnish Karelia who lived in a
more biodiverse environment (a farm, for example) had lower rates of asthma than their peers[78].
Such dramatic natural human experiments are few in number, but one human difference which is
very common is that between the children of farmers and nonfarmers. The idea that residing on
a farm, where exposure to microorganisms is commonplace, could protect against asthma and
many other diseases has a long history[79].

A host of studies have found farm living in

general[80–82] and exposure to animals and dirty work on farms in particular[83; 84], as
protective against the development of wheeze and asthma. One intriguing element of these
studies, and one certainly most suggestive of a microbial factor in the differences found, is that
exposure to endotoxin, a component of gram negative bacterial cell walls, negatively correlated
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with the development of asthma in children on farms[85]. Perhaps most striking was that the
inverse association between endotoxin and asthma was most prominent in nonfarmers. In other
words, endotoxin exposure has an outsized influence on asthma development if one does not
grow up on an already-dirty farm[85].
The inverse correlation between endotoxin and asthma outside the farm has been found
repeatedly and worldwide[86–88]. More recently, the association has been extended beyond
bacterial endotoxin to encompass a number of bacterial and even fungal products, with the
combined

effect

of

microbial

product

exposure

providing

protection

from

asthma

development[89]. Interestingly, this study found the greatest protection came in the middle of the
range of exposure levels, with those exposed to the highest levels of microbial products actually
at higher risk of developing asthma. Too much of a good thing, even when it comes to the
microbiome, can be a problem.
However, assessing exposure to endotoxin and other microbial products is relatively nonspecific.
It may be able to tell you which microorganisms are behind the exposure in a general sense (e.g.
gram negative bacteria producing endotoxin), but it cannot give specifics, such as genus or even
class or phylum, of which organisms are behind the exposure. A growing number of studies have
sought to change that, and today we know of multiple distinct microbial populations that may
protect from or predispose to asthma[90–100]. While many differences exist between studies,
two commonalities that have arisen relate to Firmicutes and Clostridium difficile. C difficile, an
enteric microorganism most known for its pathogenic properties, was found to predispose to
asthma[100], an important reminder that just as too much overall microbial exposure may be a
bad thing, not all individual microorganisms are protective. Contrastingly, increased contact with
organisms of the gram-positive phylum Firmicutes conveys asthma protection[92; 94; 97; 98;
101]. As gram positive organisms, the influence of Firmicutes would have escaped notice in
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earlier studies of endotoxin levels, further underscoring the need to assess the specific members
of the microbial community if we are to identify targets for asthma therapy.
Unfortunately, but perhaps not surprisingly, there appears to be no single microorganism or group
of microorganisms common amongst all studies, suggesting that it may be broader exposure to
microbes (as hinted by earlier work studying farms and endotoxin) that is protective. Indeed,
many of the aforementioned microbiome assessments have found that the greater the diversity
of microorganisms that one encounters as a child, the lower the lifetime risk of asthma[92; 95].
However, other studies have shown no link between overall microbial diversity and asthma
development[93; 96–98] or even a tendency toward asthma development with increased microbial
diversity[99].

Our understanding of how microbial diversity can impact asthma is clearly

incomplete, and whether more or less is protective remains to be determined.
Among existing studies are several which point to fungi, rather than bacteria, as protective against
asthma. Both individual fungal genuses, such as Eurotium[92] and Cryptococcus[96], and overall
fungal diversity[96] have been linked to protection from asthma. There is a relative paucity of
information available on the fungal microbiome, particularly in its relationship to asthma, and more
study in this area is needed to determine which host-fungal relationships drive asthma protection.

The Dangers of Very Clean Living
Dirty living may be beneficial, but isolating which factor or factors is responsible for the increase
in asthma seen in “cleaner” populations is challenging given the number of variables involved.
Two “very clean” factors that have shown particular association with asthma are delivery by
cesarean section (CS) and exposure to antibiotics, particularly early in life.

Cesarean Section
One of the earliest (although perhaps not the earliest given recent reports of the placental
microbiome[102]) exposures to microorganisms occurs during vaginal delivery, when the infant
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encounters the diverse flora of the vaginal tract. However, delivery by CS bypasses the vagina,
sparing the infant contact with vaginal flora. Put another way, all children begin life with a clean
slate, but a CS-delivered infant may start life with an even cleaner slate. The impact of this missed
contact is not simply theoretical. Evaluating the microbiome of infants delivered by CS or vaginally
demonstrated that both infant groups had relatively homogeneous microbial communities across
their body sites, but those infants delivered by CS had microbiomes similar to that of the mother’s
skin, while infants delivered vaginally had microbiomes similar to that of the mother’s vagina[103].
Such differences may have lasting consequences. A meta-analysis of 23 clinical trials comparing
vaginal birth to CS found higher odds of developing asthma when the delivery mode was CS[104].
Subsequently, large studies evaluating hundreds of thousands to millions of children, in some
cases over many decades, in Norway[105], Scotland[106], and Denmark[107] have also shown
CS to be a risk factor for asthma development, among other diseases.

The precise

microorganisms responsible, and the mechanisms by which they shape host physiology, are not
yet completely understood, but it is clear that missing early exposure to the diverse microbiome
of the vagina may have lasting consequences for human health.

Early-Life Antibiotics
The introduction of antibiotics into clinical practice has saved countless lives, and one need only
look to growing panic over rising antibiotic resistance to understand the necessity of antibiotic
use[108]. Unfortunately, we are discovering that antibiotics may affect the development of asthma
even as they protect us from truly deadly pathogenic microorganisms.

We know that the

microbiome, or at least the gut microbiome, rapidly changes in early life[109; 110], and that
antibiotic treatment can have lasting effects on both the microbiome and the host[110; 111]. Many
studies have linked early-life antibiotic exposure, particularly in the first year of life, to the
development of asthma, and the effect has been reported in populations from Seoul to the United
States[112–115]. Indeed, a meta-analysis of 20 studies of antibiotics in the first year of life found
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that it was associated with greater than 50% higher odds of asthma development[116]. This is
not a phenomenon isolated to humans. Antibiotic administration can lead to allergic asthma
development in mice[117], and at least one study has reported that neonatal, but not adult,
antibiotic exposure produces more severe allergic airway inflammation [118].

The Microbiome Governs the Immune System
Thus far, our discussion of links between the environmental exposures and human health has
been on associations, not mechanisms. Knowing that farm living is protective from asthma is
certainly important, but it provides little in the way of directly-targetable options for asthma
treatments, save perhaps that a prescription option for the pediatrician should be “farm work”.
Asthma is an immune-mediated disorder, and the next important consideration is how the
microbiome affects the immune system, and how some of these effects have been tied to asthma.
The relationship between the microbiome and the host immune system is one of the most
important concepts to have arisen from the field of microbiome research. Today, we know that
the microbiome affects all aspects of immunity, from the development of specific immune cell
types to the formation of immune organs and tissues[119–123]. The following section will explore
some of the most important microbiome-immune associations with respect to asthma
pathogenesis and pathophysiology. Importantly, most of what we know about microbiomeimmune interactions comes from work in mouse models of asthma, and unless otherwise
indicated, all reported relationships are from experimental asthma in laboratory mice.

Immune Regulation: Tregs and DCs
The ability of the microbiome to influence regulatory arms of the immune system, particularly
Tregs, has fundamentally changed our view of what the microbiome means for host immunity and
for asthma control. One of the earliest specific links was made to Bacteroides fragilis, which is
able to induce Tregs in the mouse gut[124]. We later learned that this is mediated through
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sensing of the B. fragilis polysaccharide A (PSA) by toll-like receptor 2 (TLR2)[125], and that loss
of PSA leads to a Th17 rather than a Treg response to B. fragilis[126]. This balance between
Treg and Th17 immunity could have implications for severe, neutrophilic asthma, where perhaps
a deficiency of Tregs leads to Th17 dominance.
B. fragilis is not the only microorganism capable of inducing Tregs. Just a few years after the
discovery of PSA’s role, another group reported that a mixture of organisms in the class Clostridia
could induce Tregs not only in the gut but also systemically[127]. Soon thereafter, the mechanism
became clear: Clostridial metabolism of dietary fiber to produce short chain fatty acids (SCFAs),
particularly butyrate but also propionate, which then act through the receptor GPR43 to induce
Tregs[128–130]. Further work narrowed down the responsible Clostridia to a specific group of 17
organisms within clusters IV, XIVa, and XVIII[131]. Interestingly, this is one instance where
mechanism preceded organism, as the role of SCFAs and GPR43 in Treg induction was identified
four years prior, with a report demonstrating that a lack of GPR43 increased the severity of
experimental asthma in mice[132].
The importance of SCFA production to asthma has become increasingly evident. Multiple groups
have shown that putting mice on a high fiber diet[133; 134] or directly feeding them SCFAs[134]
is protective from experimental asthma. One of these studies provided important insight into how
gut microbial metabolism can impact the lung. Those investigators found that SCFAs travel to
the bone marrow and promote the development of DCs that are highly phagocytic but poorly able
to induce Th2 responses[133]. This DC phenotype is similar to that of tolerogenic DCs, known
Tregs inducers[46].
Beyond these organisms, other bacteria linked to Tregs include Bifidobacterium infantis[135],
Helicobacter pylori[136–138], and Lactobacillus johnsonii[139].

Interestingly, the protective

mechanism of both H. pylori and L. johnsonii appears to mirror SCFAs; namely, induction of a
similar population of Treg-promoting regulatory DCs[136–139].
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L. johnsonii was found in

abundance in the house dust of homes with dogs, further evidence for the role of a “dirty”
environment in providing protection from asthma[139].
One Treg-microbiome relationship whose prominence has greatly increased over the past decade
has been the notion that parasitic infection can influence Treg development[140]. Parasites
including Heligmosomoides polygyrus[141–145], Schistosoma mansoni[146], and Strongyloides
ratti[147] have all been found to be inducers of Tregs. H. polygyrus infection has also been shown
to protect against experimental asthma, either by transfer of parasite-induced regulatory cells or
by direct host infection[141; 142; 145]. The mechanism by which H. polygyrus induces Tregs
appears to be indirect, with the parasite seemingly influencing the composition of the overall gut
microbiome, including through promotion of Lactobacillus species[144] and SCFA production by
other gut microbiome community members[145], to promote Treg induction. The reasons for
parasite Treg promotion may be entirely selfish: without Tregs, at least one of the parasites (S.
ratti) is quickly killed by the host immune system[147].
Unfortunately, the available human data on microbiome Treg induction are mixed. A study over
10 years ago lends support to the regulatory DC axis, as human blood DCs cultured with two
Lactobacillus species switch phenotype to one that drives development of a population of Tregs
which are particularly potent suppressors of effector T cell proliferation[148]. However, B. fragilis
and Clostridial species in cluster XIVa represent a more complicated story. One available clinical
study links abundance of these microorganisms at infancy to increased asthma at age three[101].
However, these data may not be as discordant as they first appear. In the study of the effect of
day care on asthma development, children in day care had more severe wheeze as toddlers but
less asthma by age six[77], suggesting that early promotion of asthma may belie protection from
disease later in life. For SCFAs, human clinical data are supportive but mixed. Maternal intake
of acetate but not butyrate or propionate was associated with less wheeze and physician office
visits in the first 12 months of infant life[134]. While this study may also need to look further
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forward in time for a clear answer, it is perhaps just as possible that those SCFAs that drive mouse
Treg development are not the same SCFAs which drive human Treg development.

The Balance Between Th2 and Th17 Responses
The microbiome may also play a role in driving asthma phenotype polarization.

Antibiotic

treatment in early life, in addition to predisposing to asthma in general, is capable of driving the
systemic immune system in a Th2 direction[101], potentially promoting the development of
allergic, eosinophilic asthma.

In germ-free (GF) mice, who are born and live without a

microbiome, the immune system is polarized in to produce Th2 responses that are incapable of
being suppressed[149]. Together, these two studies suggest that the rise in asthma seen with a
poorly-diverse microbiome may arise from polarization of the human immune system in a Th2
direction.
One interesting element of the Th2 polarization process which could have microbial involvement
relates to pulmonary uric acid production.

In 2011, one group reported that induction of

experimental asthma in mice was accompanied by uric acid production in the airways, and that
this uric acid production induced a Th2 response that was diminished by the addition of
uricase[150]. Most interestingly, this seemed to apply to human asthmatics. Assessment of the
BAL fluid of asthmatics revealed that they had higher uric acid levels than controls, and that those
individuals with higher uric acid levels tended to produce stronger Th2 responses when
challenged with allergen[150]. Where, then, is the microbial connection? At least one recent
study has shown that one disease state characterized by heightened uric acid, end stage renal
disease, was associated with an increase in microorganisms capable of metabolizing it (e.g.
uricase-expressing)[151]. Perhaps one therapeutic for asthma could include drugs designed to
increase the proportion of uricase-producing microorganisms, reducing the ability of pulmonary
uric acid to promote Th2 immune responses.
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As previously noted, removing PSA from B. fragilis turns a Treg inducer into a Th17 driver[126],
and similar species to which lack PSA may be drivers of Th17 themselves. Indeed, the link
between Th17 immunity and the microbiome is a strong one. In 2008, it was reported that certain
microbial organisms were required for induction of Th17 cells in the mouse gut, but they were
unable to identify the specific organisms[152]. Less than a year later, the culprit was revealed to
be segmented filamentous bacteria (SFB), an organism within the class Clostridia, family
Clostridiaceae[153].
While the evidence for SFB influencing asthma phenotype remains minimal, there is evidence for
the influence of other organisms. Haemophilus influenzae, a common respiratory pathogen, has
been found in the lungs of patients with severe neutrophilic asthma[154]. Infecting mice with H.
influenzae during the induction of experimental asthma shifts the phenotype of disease, reducing
markers of Th2 immunity, including eosinophils, and driving accumulation of neutrophils and
production of IL-17[155]. If this relationship proves to be a key factor behind human Th17-driven
asthma, it may be all the more reason to be sure that children receive the Haemophilus influenzae
vaccine. Finally, one enteric pathogen, an Enterococcus faecalis subspecies, can suppress Th17
immunity and symptoms of allergic airway disease together[156], although specifically Th2-driven
features of asthma (eosinophils, IgE) were not explored in that study. E. faecalis and similar
organisms may represent targets worth evaluating to develop a therapeutic that moderates
asthma and Th17 immunity simultaneously.

B Cells and Immunoglobulin
Unlike for Tregs, the connection between B cells, particularly Bregs, and the microbiome remains
very poorly understood.

We have some evidence that B cells need the microbiome and

microbiome-associated lymphoid tissue, particularly that of the gut, to properly develop[157; 158].
One area in which there is a body of evidence linking regulatory B cells to the microbiome actually
has its origin over a decade before the first reports linking Tregs to the same. In 1996, a
19

pioneering study reported that B10 cells, a population of Bregs characterized by production of the
anti-inflammatory cytokine IL-10, are induced by the parasite Schistosoma mansoni, although
they did not examine the phenotype of those Bregs much beyond IL-10 production[159]. Later
work confirmed this link in patients suffering from the autoimmune disease multiple sclerosis,
showing that B10 cell induction accompanied either Trypanosoma cruzi or Paracoccidioides
brasiliensis infection[160]. More recently, two studies have shown that recognition of microbial
antigens through TLRs[161] and the TLR signal mediator MyD88[162] produce B cells which can
suppress inflammation during microbial infection. One recent experimental study demonstrated
that S. mansoni can induce B10 cells (together with Tregs) and that transfer of the B10 cells to a
naïve, non-infected animal is protective against experimental asthma[146]. While more work
remains before this parasite-B10 axis can be targeted for asthma therapies, it is an exciting area
of research and one further potential explanation for why a dirty childhood (including, perhaps,
parasitic infection) can protect against asthma.

Innate Lymphoid Cells (ILCs)
ILCs, previously discussed as being players in the Th2 response, have also been linked to the
microbiome[163], but the evidence that a microbiome-ILC-asthma axis exists remains tentative at
best. We know that ILCs can interact with the microbiome[163], although the dependency of ILCs
on microorganisms remains very poorly understood. The relationship between the two may be
indirect. Two recent studies have shown that ILCs, specifically ILC3s, can modify the expression
of membrane-bound receptors and signaling molecules on epithelial cells and that this
modification changes how the epithelium interacts with the microbiome, including host
susceptibility to pathogenic microbial invasion[164; 165]. With respect to asthma, one study has
shown that antibiotics promote the allergic response to mold spores in mice, and that this
response depends on IL-13 production[117]. Given the growing recognition that ILC2-produced
IL-13 is a factor behind Th2-driven asthma (as previously discussed earlier in the chapter), this
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disease exacerbation could be a result of antibiotic alteration of the microbiome subsequently
impacting ILC development or function. Many more questions than answers remain in this area,
and it is likely that we will learn much more about the relationship between the microbiome and
ILCs in the coming years.

What About the Locals? Enter the Lung Microbiome
Prior discussion has centered on the how the microbiome of the gut may influence immunity in
the lung but has not touched on the influence of the local lung microbiome. Despite the obvious
potential relevance of the lung microbiome to asthma, this relationship, as with so many things
related to the lung microbiome, remains poorly understood. This deficit is, to a large extent, an
accident of history.

While we have known for well over a century of the existence of gut

microorganisms[61], the lung microbiome was long considered to be sterile in the absence of
active disease[166–170] and was correspondingly excluded from the sites explored in the first
Human Microbiome Project[71]. Today, we know that even healthy lungs harbor a microbiome,
although precisely how it interacts with the pulmonary immune system and what constitutes a true
“healthy” microbiome remain matters of great debate[171; 172].
In asthma, we know precious little, although some patterns are beginning to emerge. One
common finding has been the association of Proteobacteria species with increased severity of
asthma in BAL fluid from human asthmatics[173–176]. The explanation may return to Th17
induction, as one of these studies reported that genes related to Th17 immunity were upregulated
in those individuals harboring abundant Proteobacteria[176]. It may also return to H. influenzae,
as that microorganism happens to be a member of phylum Proteobacteria. When it comes to
diversity of the lung microbiome, limited evidence suggests that the same patterns that hold true
in the gut (i.e. higher diversity tends to be better for health) may not apply, as at least one large
clinical study found higher diversity in asthmatics and bacterial burden in asthmatic lungs when
compared to controls[174].
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Just as early life gut microbiome exposures and perturbations appear to affect lifelong asthma
risk, so too goes the lung. Two cohort studies of the human infant respiratory microbiome reported
that the infant lung microbiome, like the gut, changes rapidly[177] but that colonization with
Streptococcal organisms was a strong predictor of wheeze or asthma[177; 178]. One of these
studies also mirrored results from adult asthmatics, reporting an association between two
Proteobacteria, Moraxella catarrhalis and H. influenzae, and development of wheeze and asthma
at 5 years of age[178].
The lung microbiome is one area where clinical evidence may outnumber experimental work,
which remains exceedingly limited. One recent study may provide experimental support for the
negative influence of Proteobacteria. In this report, newborn mice tended to produce exaggerated
Th2 responses in an experimental asthma model, even in the face of high numbers of thymicallyderived Tregs in the lungs[179]. However, as the lung microbiome bacterial load increased,
Gammaproteobacteria were replaced by Bacteroidetes with a concomitant increase in iTregs, the
very Treg population also generated by gut Treg inducers. This increase was evidently driven by
interactions involving the cell surface receptor PD-L1. When challenged with allergen after this
shift, mice were more resistant and developed less disease, and the exaggerated Th2 response
disappeared[179]. Asthmatics, at least of the Th2-driven variety, may have seen the shift from
Proteobacteria to Bacteroidetes either not occur or occur incompletely, imparting a
correspondingly heightened risk of developing asthma on encountering an allergen.
In the past year, two elegant studies have shown that we may be able to manipulate the lung
immune system through application of inhaled bacterial products. In one, endotoxin or farm dust
(which contained endotoxin as well as a host of other microbial products) was administered
intranasally to mice followed by the induction of experimental asthma[180]. Either endotoxin or
farm dust suppressed the development of allergic disease through a mechanism mediated by
induction of an immunosuppressive protein known as A20. Interestingly, this result conflicts with
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at least one published clinical study, where higher levels of endotoxin were noted in the BAL fluid
of asthmatics[175]. However, this could be another case of too much of a good thing, and perhaps
the endotoxin burden in the human asthmatic is beyond that level at which it is capable of
providing benefit. In the second study, a different bacterial product, flagellin, was administered
simultaneously with the experimental allergen ovalbumin (OVA) or the common human allergen
house dust mite (HDM). Whether administered with HDM or OVA, flagellin was found to protect
from allergic airway inflammation[181]. The mechanisms of action, while not fully defined, may
rely on regulatory DCs and Tregs, as administration of flagellin to human DCs polarizes them
toward a regulatory, Treg-inducing phenotype[181].

Therapeutic Targets and Interventions for the Microbiome
We have recognized a relationship between the microbiome and asthma for many years, and it
is perhaps surprising that we have no effective microbiome-based therapies to treat or prevent
asthma.

This paucity of therapies is not for lack of effort.

Consider probiotics, or live

microorganisms administered to provide a health benefit[182]. A number of experimental studies
have fed mice probiotic microorganisms, or their products, particularly Lactobacillus spp., and
found protection from experimental asthma[183–188].

This protection has been variously

attributed to increased signaling through TLRs[183], increased numbers of systemic regulatory T
cells[185; 187], and increased production of anti-inflammatory substances including IL-10 and
TGFβ by macrophages[186]. However, a meta-analysis of 25 clinical trials of probiotics failed to
show any beneficial effect of probiotics on asthma development[189]. While the reasons for the
lack of translation from the mouse to the human remain unclear, one possibility is that adding a
single microorganism or product has too small an effect to overcome any disease predisposition.
It is worth noting that the only clinical microbiome therapy in widespread use today involves
treatment with an entire microbial community, not just a few microorganisms. That treatment is
fecal-microbiota transplantation (FMT) for antibiotic-resistant C. difficile colitis[190–192].
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Successful asthma therapy using the microbiome may need to take a page from the C. difficile
playbook and look beyond the addition of just one or even a few organisms at a time.
That said, perhaps live organisms are not the answer. Consider the deep pool of evidence
reviewed herein, both clinical and experimental, that endotoxin exposure prevents asthma
development. Administration of endotoxin to children, or even adults, may provide replacement
for our missing microbial friends and protection from asthma development. Indeed, perhaps such
supplementation should go beyond endotoxin and administer a cocktail of microbial products,
including endotoxin but also including fungal components and bacterial polysaccharides.
Unfortunately, we may correct one problem and cause another, as at least one study shows that
endotoxin and beta glucan shift the profile of asthma from Th2 to Th17[193].
Another potential option is the prebiotic, or a substance which is not alive but which modifies our
microbiomes or is utilized by our microbiomes to produce a health effect[194]. Dietary fiber is a
potent modulator of both the microbiome and (through microbial metabolism) the immune system,
and perhaps increased dietary fiber will prove effective in preventing asthma. At least one active
clinical trial is assessing this very question[195]. Several studies have looked at another prebiotic,
oligosaccharides[196; 197], by administering them to human infants and assessing asthma
symptoms later in life. Unfortunately, results are mixed, with one study reporting that wheeze was
reduced later in life[196] and others reporting no effect on wheeze[197; 198]
A final point to consider is the relationship between early-life interventions, particularly antibiotics
and CS, and asthma. Avoiding all antibiotics in childhood would be foolish, and see many children
suffer from diseases that are easily cured, just as avoiding CS entirely would see many children
and mothers die during high-risk deliveries. However, both risk factors can be mitigated without
unduly increasing danger to patients. CS should only be performed when medically warranted,
not as an elective procedure, as recommended by the American College of Obstetricians and
Gynecologists[199] and the United Kingdom National Institute for Health and Clinical
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Excellence[200]. For antibiotics, parents and physicians should carefully consider when to use
antibiotics and when to not. If a child’s infection is deemed most likely to be viral, administering
an antibiotic is not only costly but unnecessary and without benefit[108]. Indeed, there is evidence
that providing a prescription for an antibiotic, but telling patients not to fill it unless they do not get
better within a few days, produces better health outcomes than simply prescribing antibiotics for
every upper respiratory infection that enters the clinic door[201]. For the cases where CS,
antibiotics, and other hygienic interventions prove necessary, one means to potentially avoid ill
effects could be FMT or other microbiome transplantation to correct the perturbation of the
microbiome following treatment or intervention. Recently, evidence that such corrections could
prove feasible was published in relation to CS. This report revealed that the microbiome can be
“corrected” following CS[202], although no study has yet evaluated whether such interventions
have any impact on the development of asthma or other disease.

Lost in Translation: Why Mice?
In the study of any human disease, asthma not excepted, one of the principle questions a
researcher need ask is in what system they will undertake their work. Perhaps the most obvious
choice would be to study human disease in the human system itself. Why, then, do so many
studies, both in asthma and in other diseases, utilize animal models, particularly laboratory mice?
One important consideration, particularly when it comes to an immunologic disease, is the ease
with which the system lends itself to detailed mechanistic analysis. Isolating the immunologic
pathways and mechanisms responsible for asthma pathophysiology requires that we are able to
access tissues that, in a human, would be impossible or unethical to study absent extraordinary
circumstances.

For example, consider the study of Treg induction mediated by the lung

microbiome and PD-L1[179]. Obtaining such access to lung tissue to determine this relationship
would have been nearly impossible, if not altogether impossible, were humans the study subjects.
Something as simple as access to the lymph nodes draining the lungs would be less challenging
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but would still require invasive surgery that would be difficult to justify in a human as compared to
a mouse.
However, the ability to precisely dissect immunologic pathways and the effects of experimental
interventions may be meaningless if those dissected pathways, genes, and other players have no
relevance for human disease. The dangers of this were illustrated in a 2013 report[203] that was
widely commented on in the scientific and popular literature. In this study, the gene expression
responses in the blood of mice and humans were compared in several inflammatory responses
including trauma and sepsis. The investigators found little to no correlation between the species
and concluded that the inflammatory response of the mouse differs too greatly from the human to
be relevant for research[203]. This conclusion ignited a firestorm of controversy, with subsequent
studies and commentaries[204] declaring that mice were alternatively useless and essential for
biomedical research. In 2015, the waters were further muddied by a reanalysis of the original
2013 dataset, where a different team applied what they believed was a more appropriate analysis
and found much similarity between the mouse and human inflammatory responses[205]. The
debate has continued, with the authors of the original publication and others unrelated to either
group declaring that one or the other assessments is not valid[206; 207]. While the exact
relevance of the mouse to human research may remain unquantifiable for the immediate future,
it is likely that the true answer falls somewhere between the extremes. Indeed, while one may
question whether all mouse discoveries are directly applicable to humans, the available evidence
suggests that at least some in the field of immunology and asthma (for example, that
microorganisms can cause human dendritic cells to promote Treg development[148]) will prove
to be shared between mice and men.
That said, the hopeful microbiome mouse researcher is confronted with an uncomfortable reality
when it comes to improving human health: the veritable cordillera of published work has yet to
translate into more than a handful of meaningful health advances, particularly with respect to
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asthma. For many discoveries, such as the protective effect of prebiotic dietary fiber for murine
asthma[133], the science is simply too new for an effect to have even been formally evaluated in
humans. For others, particularly probiotics, we have excellent evidence of efficacy in mice[183–
188] but poor evidence in human clinical trials[189]. This problem of poor translatability goes
beyond asthma. Many fields have long bemoaned the failure of science to take findings in animal
models and turn them into clinical advances, with many clinical trials based on promising
preclinical animal data failing to show a benefit in man[208].
While one may be quick to blame the mouse, the true impediment to translation may be the human
researcher. There is growing evidence that humans conducting less than rigorous animal studies
are behind the failures of many promising preclinical results to show efficacy in humans. Consider
the study of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Efforts by
ALS researchers to replicate the preclinical findings of dozens of mouse trials failed to replicate
any when repeated in separate groups of mice[209; 210]. Many of these preclinical findings had
failed to reproduce in humans, an unsurprising result when one considers that the original tests
may have failed in mice in the first place. Indeed, efforts to blame the mice may also be obscuring
significant concerns in human clinical studies. A recent analysis of 100 human psychology studies
found that only 39% of reported effects were replicated, even with assistance from the authors of
the original studies in designing the replications[211]. While some of the problem may lie in poor
study design, part of the difficulty lies in the nature of the human animal. Unlike laboratory mice,
humans are highly heterogeneous in behavior and lifestyle. Furthermore, while humans are far
from genetically divergent from each other, even small genetic variations can produce enormous
differences in responses to treatment[212].

Understanding these differences, and targeting

therapies based on genetics, has blossomed into the distinct field of pharmacogenomics[212],
and this may be another reason still for failures of animal studies (which benefit from highly
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genetically homogeneous populations) to translate to human benefit. Mouse studies may have
challenges and obstacles aplenty, but human studies carry just as many, if not more.
To abandon mice, however attractive it may seem, is to also abandon the rich legacy of discovery
animal models have constructed. In immunology, many fundamental concepts have their roots
in animal research. Consider the discovery of antibodies. Over a century ago, Behring and
Kitasato described the protective effects of “antisera” against tetanus in rats and rabbits long
before such concepts were extended to man[213; 214]. In the realm of asthma, similar animal
discoveries abound. Cortisone, the first corticosteroid isolated, was found through the study of
bovine adrenal glands nearly 90 years ago by Hench and Kendall[215], and any asthmatic who
uses a steroid to control airway inflammation owes a debt of gratitude to those ruminants. The
refinement of beta2-adrenergic agonists, the selective bronchodilators that save untold millions
of asthma sufferers from serious morbidity and suffering, arose from detailed studies in
animals[216]. Indeed, prior to the discovery of these specific receptor agonists, nonselective
sympathomimetics such as epinephrine, which bronchodilate at the cost of a host of undesirable
systemic effects, were the only means to provide relief to asthma sufferers[217]. Lest one think
that only “old” medicine benefitted from animal work, consider omalizumab, the anti-IgE
monoclonal antibody used today in the treatment of moderate to severe asthma[218]. Creating
and refining this therapeutic so that it would provide specific IgE blockage without unwanted side
effects (i.e. mast cell degranulation) took place in mice long before the drug was ever tested in
humans[218].
Finally, there is cause for hope that mice may be an entirely appropriate platform for human
microbiome studies. Mouse and human microbiomes, at least in the gut, do have similarities,
although many of these are at higher taxonomic levels (i.e. phylum) rather than at the species
level[219; 220]. One argument against reading too much into the dissimilarity of mouse guts from
those of humans is that many studies only examine the guts of one strain of mice (often from one
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supplier). We would do well to consider the microbiomes of all mouse strains together when
comparing to humans. While variation would surely increase, variation is the currency of the
human species, and we might find that the microbiomes of many different strains of mice together
mimic the broader human microbiome. Perhaps future mouse studies of asthma will compare
farm mice to conventional laboratory-raised animals, and the same patterns seen in human
children may surface but now in a system amenable to manipulation and close, detailed study.
Or, absent exact match between natural mouse microbiomes and human ones, we may be able
to make mice more human. Transfer of human gut microbiomes to mice has shown that these
microbiomes can implant stably, with relatively few differences from the original, donor human
microbiome[70; 221]. Indeed, such transplants can even prompt physiologic changes, as we
have previously noted with the gut microbiomes of obese and lean twins[70].

Conclusion, Hypothesis, and Project Overview
When it comes to the microbiome and asthma, the common rule of the microbiome applies: we
recognize that there is an important relationship between the two, but we are only beginning to
decipher precisely what that relationship is and which players direct it. Advances in the realm of
microbiome-immune interactions have fundamentally changed our view of how microorganisms
can regulate asthma, particularly when it comes to Tregs, but a host of questions remain to be
answered. How can we harness microbial modulation of Tregs to control asthma? Is the
microbiome responsible for the switch from Th2-driven, eosinophilic asthma to the severe, Th17driven phenotype? Importantly from a translational research perspective, we recognize broad
patterns in humans, such as early-life farm and endotoxin exposure and a lack of antibiotic
exposure, in asthma development, but we have yet to understand how to harness these broad
patterns to influence human disease.
The laboratory of Dr. Roger Thrall has made the study of regulation in asthma the subject of
several decades of research. During that time, the lab utilized the experimental ovalbumin model
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of allergic airway disease to first show that continuous, long-term inhalational exposure to
ovalbumin induces a tolerant state, where further exposure to ovalbumin produces no appreciable
disease[222]. Exploring this process of tolerance further, we demonstrated that Tregs accumulate
as tolerance develops and experimental asthma is suppressed[31], that Bregs may interact with
Tregs to promote this process[41; 42], and that other cells, including DCs[47] and natural killer
cells[223], may have important roles to play in control of disease. Most recently, we have found
that many of these principles extend beyond one asthma model and are, while not identical, very
similar in a model utilizing the clinically-relevant human allergen house dust mite[32].
We are all exposed to allergens, the causative agents of Th2-driven asthma, but only a few of us
ever develop asthma.

It is possible that those of us who do not develop asthma actually

experience disease but quickly develop tolerance to the offending allergen, potentially explaining
the paradox of daycare children being at risk for early asthma but receiving protection later in
life[77]. One potential driver of tolerance in some but not all people could be the microbiome.
Our group has previously shown that regulatory elements of the immune system drive tolerance
to inhaled allergens, and many microbiome researchers have shown that the microbiome drives
regulatory elements of the immune system. However, efforts to link tolerance in asthma to the
microbiome have been minimal at best. For my dissertation research, I took the expertise of the
Thrall Laboratory in immune regulatory mechanisms in asthma and extended it to the microbiome,
focusing on the following overarching hypothesis in the lab’s house dust mite (HDM) model of
allergic airway disease:
Exposure to antibiotics early in life increases the severity of asthma through microbiomedependent reduction of regulatory T cells (Tregs).
To evaluate my hypothesis, my dissertation traveled two parallel roads. On the first, I evaluated
how the microbiome changes as experimental asthma progresses from disease to tolerance,
linking these changes to shifting disease parameters. For the second, I disrupted the microbiome
30

using antibiotics and evaluated its impact on the development of disease and on the development
of tolerance. The following chapters will detail the results of my endeavors in these areas as well
as the future directions and potential clinical and scientific impact of my results on both
microbiome research and asthma clinical care.
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Figures
Box 1: Microbiome, Microbiota, or Metagenome?
Box 1. Microbiome, Microbiota, or Metagenome? The field of microbiome research utilizes many
specific terms, and unfortunately some of these have no universally accepted definition,
particularly microbiome[224]. Some researchers consider the word “microbiome” to be derived
from a joining of the word “microbe” and suffix “ome”, implying all the genomes of all the
microorganisms in a community. A second definition is broader, pairing the prefix “micro” with
the word “biome” and implying the sum of all organisms, their activity, and their genes.

As

originally popularized by Joshua Lederberg, microbiome was closer to the latter, defined as “the
ecological community of commensal, symbiotic, and pathogenic microorganisms that literally
share our body space”[60]. Such a definition seemingly encompasses the organisms, their
interactions with each other, and their interactions with the host (the entire biome, if you will).
Furthermore, this definition fits with classic use of the term.

In work dating to 1988[225],

1952[226], and even 1949[227], the microbiome referred to the entire ecological community of
microorganisms and their interactions with their environment. I prefer to use microbiome in its
classical sense, to refer to the sum of all the organisms, their genomes, and their environmental
interactions. When discussing only the organisms, I shall use the term microbiota. To speak of
the genomes of the microorganisms, I shall use the term metagenome.
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CHAPTER 2
MATERIALS AND METHODS
Animal Subjects
C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). For studies of
allergen exposure and microbiome changes (no antibiotics included), female mice were
purchased at 6-8 weeks of age. For studies of early-life antibiotic (ABX) exposure, nursing
mothers with female pups were purchased at three weeks of age and upon receipt were
immediately weaned and ABX treatment initiated. For studies of the effect of ABX throughout life
on tolerance, pregnant mice were purchased and treatment initiated a few days prior to giving
birth. Mice of both sexes were used for the latter studies.
Mice were housed conventionally in plastic cages with corncob bedding in the Center for
Comparative Medicine at UCONN Health. Animal rooms were maintained at 22-24°C with a daily,
12-hour light/dark cycle. Chow and water were supplied ad libitum. Animal care and use was
approved by the Institutional Animal Care and Use Committee at UConn Health, protocol
#100983-0717.

House Dust Mite (HDM) Model
The HDM model of allergic airway disease (AAD) was performed as described in [32]. Briefly,
mice were lightly anesthetized with vaporous isoflurane and intranasally (i.n.) instilled with
droplets containing 25 μg lyophilized HDM extract (equal mixture of Dermatophagoides
pteronyssinus and D. farinae, Greer Laboratories, Lenoir, NC) solubilized in 50 μl phosphate
buffered saline (PBS). HDM was administered for five consecutive days, followed by two days of
rest, for up to eleven consecutive weeks (Fig 1). Control groups received equal volumes of i.n.
PBS in a time-matched manner. For studies assessing the active disease phase, mice were
sacrificed after either short-term (two week) or intermediate-term (five week) HDM exposure time
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points. For studies of tolerance, mice were sacrificed at after long-term (eleven week) HDM
exposures. All mice were sacrificed 72 hours post final HDM challenge.

Broncho-Alveolar Lavage (BAL), Blood, and Tissue Collection
To obtain BAL fluid and cells from mice, the trachea was exposed and cannulated at time of
sacrifice. Lungs were lavaged in situ with 5 mL of sterile saline in 1 mL aliquots and BAL cells
pelleted at 600xg for ten minutes at 4°C. Hilar (lung-draining) lymph nodes (HLN) were removed
and mechanically disrupted into single-cell suspensions and filtered through a 100 µm Nytex
screen (ELKO Filtering Co, Miami, FL). Lavaged half lungs (left lung) were digested with 150
U/mL collagenase (Gibco/Thermo-Fisher Scientific, Waltham, MA; Cat #17018-029) and
mechanically disrupted into single-cell suspensions, after which erythrocytes were lysed using
Tris-buffered ammonium chloride (TAC) solution (9 parts 0.83% w/v ammonium chloride; 1 part
2.57% w/v Tris; pH 7.0) at room temperature. For histopathologic assessment, lavaged half lungs
(right lung) were removed and fixed with 4% buffered formalin for 72 hours.
For all tissue samples, manual total nucleated cell counts were obtained using a hemocytometer
with nigrosin dye exclusion as a measure of viability. Cytospin preparations of BAL fluid were
stained with May-Grünwald and Giemsa for differential cell analysis via light microscopy.
To isolate serum, blood was collected from mice through cardiac (right ventricular) puncture at
the time of sacrifice and allowed to clot for 30 minutes. Clotted blood was spun down at 1600xg
for ten minutes and serum removed and stored at -80°C until needed for analysis.

Flow Cytometry
Cells isolated from BAL fluid, HLN, and lung tissue were subject to flow cytometric analysis using
the following monoclonal antibodies: CD3epsilon (1:200, Tonbo Biosciences, San Diego, CA;
Clone 145-2C11; Cat #35-0031-U100); CD4 (1:200, eBioscience, San Diego, CA; Clone GK1.5;
Cat #47-0041-82); CD5 (1:100, eBioscience; Clone 53-7.3; Cat #17-0051-81); CD8α (1:200,
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Tonbo Biosciences; Clone 53-6.7; Cat #80-0081-U100); CD19 (1:200, Tonbo Biosciences; Clone
1D3; Cat #35-0193-U500); and CD45R/B220 (1:200, Tonbo Biosciences; Clone RA3-6B2; Cat
#75-0452-U025). Samples were stained essentially as previously described[32; 41]. Cells were
washed in PBS containing 0.2% bovine serum albumin and 0.1% sodium azide.

Aliquots

containing 105-107 cells were incubated with anti-mouse CD16/CD32 (1:200, Fc Shield, Tonbo
Biosciences; Cat #70-0161-U500) for 15 minutes. Cells were then incubated with AlexaFluor350
as a viability marker (1:500, Invitrogen/Thermo-Fisher Scientific; Cat #A10168) and surface
antibodies for 30 minutes at 4°C.

For surface stains only, cells were then fixed with 4%

paraformaldehyde for 10 minutes. For staining of Foxp3, cells stained with surface markers were
fixed and permeablized with Foxp3/Transcription Factor Staining Kit (Tonbo Biosciences; Cat
#TNB-0607-KIT) according to the manufacturer’s instructions and stained with anti-Foxp3 (1:150,
Tonbo Biosciences; Cat #20-5773-U100) for 30 minutes at 4°C.

Samples were run with

corresponding isotype controls on a BD LSR II (Becton Dickinson, Franklin Lakes, NJ) and
analyzed using FlowJo (Tree Star Software, Ashland, OR).

Tissue Histology and Scoring
Formalin-fixed lungs were placed in tissue cassettes and sent to the Connecticut Veterinary
Medical Diagnostic Laboratory (CMVDL) in Storrs, CT for paraffin embedding, slide mounting,
and both hematoxolyn and eosin (H&E) and periodic acid-Schiff with hematoxylin counterstain
(PAS-H) staining. H&E-stained slides were used to assess gross pathologic changes, while PASH-stained sections were used to assess mucus production. Sections from all four lobes of the
right lung were evaluated in their entirety and representative images taken using a BX53 research
microscope with DP73 digital camera (Olympus, Waltham, MA).

Pathologic scoring was

performed essentially as described previously[32] with modifications made to the scoring rubric.
Five blinded reviewers simultaneously graded the same visual fields on each slide using a
multiheaded microscope.

For inflammation scores, 0 corresponded to no detectable
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inflammation; 1 to mild peribronchiolar/perivascular cuffing with inflammatory cells; 2 to significant
peribronchiolar/perivascular clustering; and 3 to significant clustering and airway remodeling (e.g.
smooth muscle hypertrophy and hyperplasia). For mucus scores, 0 corresponded to no visible
mucus; 1 to occasional and punctate mucus staining in the airways; 2 to presence of ring-like
mucus structures in less than 10% of airways; and 3 to presence of ring-like mucus structures in
greater than 10% of airways. The scale was modified from [32] in that half scores (e.g. 0.5, 2.5)
were permitted when graders determined a sample fell between two whole-number grades.

Serum Immunoglobulin Assessment
Isolated serum was assessed for HDM-specific IgE and IgG1 levels essentially as described
previously[32].

Serum HDM-specific IgE levels was determined by ELISA.

96-well Nunc

MaxiSorp flat-bottom plates (Thermo-Fisher Scientific) were coated with 10 ug/mL HDM extract
in sodium bicarbonate buffer (pH 9.5) for 48 hours at 4°C. Following coating, plates came to room
temperature for 15 minutes and were washed six times with 0.05% PBX/Tween 20 (PBST) and
blocked for one hour at 37°C with BD OptEIA Assay Diluent (BD Biosciences, San Diego, CA;
Cat #555213). After washing six times with PBST, serum samples were added in two-fold serial
dilutions (range 1:20 to 1:2560) and incubated at room temperature for 1.5 hours. Plates were
washed eight times with PBST and labeled with Biotin-SP-conjugated goat anti-mouse IgE
(Southern Biotech, Birmingham, AL; Cat #1110-08) diluted 1:5000 in blocking buffer for one hour
at room temperature.
Serum HDM-specific IgG1 levels were determined by ELISA in a similar manner to detection of
IgE. 96-well plates were coated with 2 ug/mL HDM extract in sodium bicarbonate buffer for 24
hours at 4°C. Plates were washed six times with PBST and blocked for one hour in BD OptEIA
Assay Diluent. Plates were washed six times with PBST and incubated with 10-fold serial dilutions
of serum (1:10 to 1:200,000,000) for 1.5 hours at room temperature. Plates were washed eight
times with PBST and labeled with biotin-SP-conjugated AffiniPure goat anti-mouse IgG, Fcγ
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subclass 1 (Jackson ImmunoResearch, West Grove, PA; Cat #115-065-205) diluted 1:100,000 in
blocking buffer for one hour at room temperature.
For both assays, plates were then washed six times and incubated with streptavidin HRP (BD
Biosciences, San Jose, CA; Cat #554066) diluted 1:1000 in blocking buffer at room temperature
for thirty minutes. Plates were washed seven times with PBST and incubated with 3,3',5,5'tetramethylbenzidine (TMB, KPL, Gaithersburg, MD; Cat #50-76-01) for 20 minutes in the dark at
room temperature. The reaction was stopped using 1 M phosphoric acid at equal volume to TMB
and the plates were read at dual 450nm-570nm wavelengths using an iMark Microplate Reader
(Bio-Rad Laboratories, Hercules, CA).

Airway Hyper-Reactivity (AHR) Assessment
AHR was assessed as previously described with modification[32]. Total respiratory system
resistance (Rrs) responses to increasing doses (0-300 mg/mL) of acetyl-β-methacholine chloride
(Sigma-Aldrich, St. Louis, MO; Cat #A2251) were measured by a flexiVent FX1 mechanical
ventilator (SCIREQ Scientific Respiratory Equipment, Montreal, QC, Canada).

Mice were

anesthetized using urethane (Sigma-Aldrich; Cat #U2500) administered in saline by
intraperitoneal (i.p.) injection at 0.8 g/kg - 5.0 g/kg body weight. Once insensitive to toe pinch,
respiratory muscles were paralyzed using 500 ng/kg i.p. pancuronium bromide (Sigma-Aldrich;
Cat #P1918) and mice were immediately placed under mechanical ventilation. Airway reactivity
was determined by assessing forced oscillatory mechanics every ten seconds for four minutes
following each methacholine challenge. Electrocardiogram measurements were monitored to
ensure viability for the duration of mechanical ventilation.

Antibiotic (ABX) Treatment
ABX treatment consisted of one of three regimens. Mice were exposed to either tylosin (SigmaAldrich; Cat #T6271) and amoxicillin (Sigma-Aldrich; Cat #A8523), amoxicillin alone, or a
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combination of ampicillin (Sigma-Aldrich; Cat #A0166), metronidazole (Sigma-Aldrich; Cat
#M1547), neomycin (Sigma-Aldrich; Cat #N6386), and vancomycin (Sigma-Aldrich; Cat #V1130)
in the drinking water. ABX-treated water was sterile filtered prior to placement in mouse cages
and provided to mice ad libitum. Control water was treated identically to ABX-containing water
(including sterile filtering) save for the lack of ABX.
For experiments assessing early life antibiotic exposure and AAD, the treatment schedule was
adapted from the example of Nobel and colleagues[228]. Mice were exposed to amoxicillin, ABX
mix, or control (untreated) drinking water for three four-day periods (Thursday to Sunday), with a
three day rest between treatments where untreated water was supplied, beginning immediately
after weaning (three weeks old). Following the third ABX treatment, mice were administered HDM
for five weeks according to the model described earlier. Refer to Figure 2 for a schematic of the
treatment strategy.
For experiments assessing the effect of antibiotics on tolerance development, three treatment
schedules were utilized. The first was closely adapted from Nobel and colleagues[228]. Mice
received two different ABX, tylosin and amoxicillin, in the drinking water in alternating four
alternating, four-day periods (Thursday to Sunday), with a three day rest between treatments
where untreated water was supplied, beginning immediately after weaning (three weeks old). The
first treatment consisted of 0.4 g/L tylosin, the second 0.25 g/L amoxicillin, the third 0.4 g/L tylosin,
and the fourth 0.25 g/L amoxicillin. HDM exposure began following the first tylosin exposure.
Figure 3 details this treatment strategy. The second ABX exposure model followed the early life
exposure model described previously but extended HDM exposure to eleven weeks (Figure 4).
The third was adapted from the examples of reports studying perinatal antibiotic administration
on asthma development in laboratory mice[118; 229; 230].

Here, mice were exposed to

amoxicillin, ABX mix, or control (untreated) drinking water from approximately 2-3 days prior to
birth until the conclusion of the experiment (i.e. throughout life). In both cases, mice were exposed
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to eleven weeks of HDM according to the model described earlier. Refer to Figure 5 for a
schematic of the treatment strategy.
Amoxicillin was selected because it is the most commonly prescribed ABX in childhood[231] and
it can be dissolved in drinking water and administered to laboratory mice[232]. The cocktail of
ampicillin, metronidazole, neomycin, and vancomycin (hereafter, “ABX mix”) was selected for its
demonstrated effectiveness in broadly depleting the entire gut microbiome and its ability to be
dissolved and administered in drinking water to laboratory mice[233; 234].

Microbiome Sampling and DNA Extraction
The mouse fecal microbiome was sampled by collecting fresh fecal pellets at the time of
production.

Mice were grasped by the scuff of the neck and restrained until defecation,

whereupon sterile, RNA-/DNA-/RNAse-/DNAse-free microcentrifuge tubes were used to collect
the pellet. Collected pellets were immediately placed at -80°C storage and kept frozen until DNA
extraction.
DNA was extracted using a PowerSoil DNA Isolation Kit (MoBio Laboratories, Carlsbad, CA; Cat
#12888-100) according to the manufacturer’s protocol with one modification.

At step five

(bacterial cell disruption), fecal samples were placed in PowerSoil bead tubes and samples were
bead-beaten for five minutes using a single-speed (3450 oscillations/min) Mini-Beadbeater-16
(Biospec Products, Bartlesville, OK). Extracted DNA was quantified using a Qubit dsDNA Broad
Range Assay Kit (ThermoFisher Scientific; Cat #Q32853) and a Qubit 2.0 fluorometer
(ThermoFisher Scientific Cat #Q32866).

16S rRNA Amplification and Sequencing
Amplicon library preparation, cleaning, and dilution were performed by the Microbial Analysis,
Resources, and Services (MARS) Facility at the University of Connecticut, Storrs, CT. Prior to
August, 2015, the V4 region of the 16s rRNA gene was amplified and sequenced using the
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protocol and barcoded primers (515F and 806R, with 8 basepair Golay-barcoded indices on the
3’ end) designed by Caporaso et al[235]. Approximately 20 ng of extracted DNA was amplified
in triplicate using Phusion High-Fidelity DNA Polymerase master mix (New England BioLabs,
Ipswich, MA; Cat #M0530S). The PCR reaction was incubated at 94˚C for three minutes followed
by 30 cycles of 45 s at 94.0°C, 60 s at 50.0°C and 90 s at 72.0°C. Final extension took place at
72.0°C for 10 minutes.
From August 2015, the protocol was the same as above with three modifications. The V4 region
of the 16s rRNA gene was amplified in triplicate using the dual barcoded primers (515F and 806R)
of Caporaso et al (8 basepair Golay-barcoded indices on the 3’ end[235]) and Kozich et al (8
basepair on the 5’ end[236]). Amplification was performed using 30 ng of DNA and AccuPrime
Taq DNA Polymerase (Thermo-Fisher Scientific; Cat #12342010).

The PCR reaction was

incubated at 95˚C for 3.5 minutes followed by 30 cycles of 30 s at 95.0°C, 30 s at 50.0°C and 90
s at 72.0°C. Final extension took place at 72.0°C for 10 minutes.

Comparison of the same

samples amplified by both polymerases and using both PCR reaction protocols revealed no
significant differences between the two with respect to downstream diversity or community
composition (genus-level and higher).
PCR products were pooled for quantification and visualization using the QIAxcel DNA Fast
Analysis (Qiagen, Hilden, Germany). PCR products were normalized based on the concentration
of DNA from 250-400 bp in length and pooled using the QIAgility liquid handling robot (Qiagen).
The pooled PCR products were cleaned using the Gene Read Size Selection kit (Qiagen; Cat
#180514) according to the manufacturer’s protocol. Samples were then denatured, diluted, and
sequenced on an Illumina MiSeq using v2 or v3 chemistry according to the manufacturer’s
instructions. PhiX (5-20%) was added to the run to increase sample complexity.
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Analysis of 16S rRNA Sequence Data
Sequence data were analyzed using QIIME 1.9.1 software[237] in the High Performance
Computing Facility of the Richard D. Berlin Center for Cell Analysis and Modeling. The analysis
pipeline was derived from Nelson et al[238]. Briefly, samples were demultiplexed and paired-ends
joined. A Phred quality score of 19 was used as the cut-off when splitting libraries. Joined reads
were filtered so that only reads of between 245 and 260 base pairs (bp) were kept. Chimeric
sequences were removed using UCHIME[239] within USEARCH6[240]. Operational taxonomic
units (OTUs) were picked at 97% similarity using USEARCH6[240; 241] in an open-reference
manner using the GreenGenes ribosomal database May 2013 release[242; 243] as a reference.
Results were subsampled to 10,000 sequences, and any samples falling below this threshold
were either excluded or re-sequenced until they exceeded the 10,000 sequences threshold.
Alpha and beta diversity metrics were calculated using QIIME. PCoA of beta diversity metrics
was performed using QIIME and included comparisons between groups using UniFrac
distances[244]. For taxonomic tables, only organisms which appeared with an abundance of
greater than 1% in more than one group or timepoint were represented as distinct bars. All
organisms failing this cut-off were placed in the “Other” category. These organisms were included
in all alpha and beta diversity analyses. Appendix A contains the analysis script used. Appendix
B contains the settings specified in the QIIME parameters file referenced in the analysis script.

Fecal Microbiota Transplantation (FMT)
FMT was performed in a manner adapted from[245–248]. Fresh fecal pellets were collected in
sterile saline at a ratio of approximately 1 mL of saline per 3.5 pellets. The pellet-saline mixture
was vortexed at the highest speed for 3 minutes to disperse pellets. Tubes were then centrifuged
at 300xg for one minute to pellet large particulate matter. The supernatant was drawn off, avoiding
particulate matter, and immediately frozen at -80°C until use. Prior to use, frozen FMT solution
was thawed and allowed to come to room temperature.
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To perform FMT, 200 µL of FMT solution or saline control was lavaged into the stomach (gavaged)
into mice.

Gavage was performed by firmly grasping the mouse, without anesthesia, and

advancing a 22 gauge, 1 inch stainless steel feeding needle with 1.25 mm ball time (Braintree
Scientific, Braintree, MA) into the oral cavity, down the esophagus, and into the stomach.
Contents of the syringe are then injected slowly into the stomach. Mice who has received early
life antibiotic exposure as described above received three gavages of FMT solution (Monday,
Wednesday, and Friday) in the first week following the final ABX treatment. Following the first
week of gavages, mice began HDM i.n. exposure for two weeks. During those two weeks, mice
received two FMT solution gavages (Tuesday and Thursday) per week for the subsequent two
weeks. The ABX, FMT, and HDM treatment protocol is outlined in Figure 6.

HDM Gavage
To assess oral tolerance, mice were exposed to HDM by gastric lavage (gavage). Gavage was
performed in the manner described for FMT. HDM-gavaged animals received an identical dose
to that of mice exposed to intranasal HDM, 25 μg lyophilized HDM extract (equal mixture of
Dermatophagoides pteronyssinus and D. farinae, Greer Laboratories, Lenoir, NC) solubilized in
50 μl phosphate buffered saline (PBS). HDM gavage was administered for five consecutive days,
followed by two days of rest, for eleven consecutive weeks (Figure 7A). Control groups received
equal volumes of gavaged PBS in a time-matched manner. In a second group of animals, mice
received eleven weeks of HDM or PBS gavage followed by two weeks of i.n. HDM (Figure 7B) in
the manner of Figure 1. All mice were sacrificed 72 hours post final HDM challenge.

Statistical Analysis
Statistical comparisons between two groups were made using the non-parametric Mann-Whitney
U test. Comparisons between three or more groups were made using the non-parametric, oneway Kruskal-Wallis analysis of variance (ANOVA). Multiple-comparisons between individual
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groups were made using Dunn’s multiple comparisons test or Sidak’s multiple comparisons test,
as appropriate. Comparisons of serum immunoglobulin levels and AHR were made by computing
the area under the curve (AUC) of all samples and comparing the AUCs using one-way ANOVA.
These tests were performed using Prism 6 (GraphPad Software, La Jolla, CA). Measures of
within-sample (alpha) and between-sample (beta) diversity were made using QIIME software.
Biomarker and effect size assessment for taxa were made using LDA Effect Size (LEfSe)[249] on
the Huttenhower Lab Galaxy Server[250; 251]. For all tests, a threshold of p < 0.05 was used to
determine statistical significance.
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Figures
Figure 1: House Dust Mite (HDM) model of allergic airway disease
(AAD) and tolerance

Figure 1. House Dust Mite (HDM) model of allergic airway disease (AAD) and tolerance. HDM
extract was administered intranasally to mice five days per week, Monday through Friday, for up
to eleven weeks as described in the Materials and Methods. AAD was generated by two weeks
of exposure and persisted at least through five weeks of exposure. By eleven weeks of exposure,
tolerance developed and disease was suppressed. Mice were sacrificed 72 hours following the
final HDM exposure for each timepoint (two, five, and eleven weeks).
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Figure 2: HDM and Antibiotics Exposure Model, 5 Weeks

Figure 2. HDM and Antibiotics Exposure Model, 5 Weeks. Mice received ABX exposure in an
analogous manner to that described in Figure 2.

ABX consisted of either amoxicillin or a

combination of ampicillin, metronidazole, neomycin, and vancomycin (ABX mix). Untreated water
served as a control. Following the first two ABX exposure periods, ABX-treated water was
replaced with untreated water from Monday to Thursday. HDM exposure for five weeks (five days
per week) began immediately following the final ABX exposure. Mice were sacrificed 72 hours
following the final HDM exposure.
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Figure 3: Early-Life Antibiotics and Tolerance Exposure Model:
Amoxicillin and Tylosin

Figure 3. Early-Life Antibiotics and Tolerance Exposure Model: Amoxicillin and Tylosin. Mice
received ABX exposure consisting of tylosin (ABX exposures at weeks 0 and 2) or amoxicillin
(ABX exposures at weeks 2 and 4). Untreated water served as a control. Following the first three
ABX exposure periods, ABX-treated water was replaced with untreated water from Monday to
Thursday. HDM exposure for eleven weeks (five days per week) began immediately following
the first ABX exposure. Mice were sacrificed 72 hours following the final HDM exposure.

Figure 4: Early-Life Antibiotics and Tolerance Exposure Model:
Amoxicillin and Antibiotic Mix
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Figure 4. Early-Life Antibiotics and Tolerance Exposure Model: Amoxicillin and Antibiotic Mix.
Mice received ABX exposure in an analogous manner to that described in Figure 2. ABX
consisted of either amoxicillin or a combination of ampicillin, metronidazole, neomycin, and
vancomycin (ABX mix). Untreated water served as a control. Following the first two ABX
exposure periods, ABX-treated water was replaced with untreated water from Monday to
Thursday. HDM exposure for eleven weeks (five days per week) began immediately following
the final ABX exposure. Mice were sacrificed 72 hours following the final HDM exposure.

Figure 5: Continuous Antibiotics and Tolerance Exposure Model

Figure 5. Continuous Antibiotics and Tolerance Exposure Model. To ensure sustained disruption
of the developing microbiome, mice were exposed to ABX continuously throughout life, including
during the prenatal period. ABX consisted of either amoxicillin or a combination of ampicillin,
metronidazole, neomycin, and vancomycin (ABX mix). Untreated water served as a control. HDM
exposure began at six weeks of age and continued for eleven weeks (five days per week). Mice
were sacrificed 72 hours following the final HDM exposure.
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Figure 6: Fecal Microbiota Transplantation Model

Figure 6. Fecal Microbiota Transplantation Model. Mice received ABX exposure in an analogous
manner to that described in Figure 2. During the week following the third antibiotic exposure
period (week 0), mice received 200 µL gavage of saline-suspended fecal contents three times:
Monday, Wednesday, and Friday. HDM exposure began in the following week (week 1) and
continued for two weeks. During the two weeks of HDM exposure, mice received an additional
two gavages per week (Tuesday and Thursday) of 200 µL of saline-suspended fecal contents.
Mice were sacrificed 72 hours after the final HDM exposure.
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Figure 7: HDM Gavage Model

Figure 7. HDM Gavage Model. HDM extract was administered by oral gastric lavage (gavage)
to mice five days per week, Monday through Friday, for eleven weeks as described in the
Materials and Methods (A).

Control animals received gavage of PBS alone.

The dose

administered by gavage was identical to that administered by intranasal instillation as described
in Figure 1. After eleven weeks of gavage, half the HDM-gavaged and half the PBS-gavaged
mice were sacrificed and assessed using the cellular and immunologic parameters described in
the Materials and Methods. The remaining half of the HDM- and PBS-gavaged mice were
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CHAPTER 3
THE IMPACT OF INHALED AND ORAL HDM EXPOSURE ON THE
GUT MICROBIOME
Introduction
Immunologic tolerance (henceforth, “tolerance”) is the process by which the immune system does
not react to an encountered substance, cell, or other recognizable antigen. Perhaps the most
classic example of tolerance is the inability of the immune system to attack self tissue absent
pathologic autoimmunity[252]. However, tolerance extends beyond self tissue and includes many
non-self substances. One obvious example is food: we take in large quantities of food daily, all
of which his decidedly foreign, but our body is normally able to tolerate the presence of food and
not react to it[253]. Indeed, failure of the body to tolerate the presence of food is the source of
many devastating food allergies, where the body reacts to entirely-harmless foods such as
peanut[254] or the wheat protein gliadin[255], the latter reaction being the source of celiac
disease.
Just as food allergy is a failure of immunologic tolerance, so too is allergic asthma (hereafter,
“asthma”). The airway inflammation that is so characteristic of the disease is a result of that failure
of tolerance against otherwise harmless inhaled allergens[256]. Work from our group[32; 222;
257] as well as several others[258–261] has shown that tolerance and suppression of asthma can
be generated through prolonged inhalational exposure to the offending allergen. However, these
experimental systems have important differences from human asthma. In mice, exposure to OVA
or HDM always consistently produces the development of tolerance, whereas a minority (albeit a
significant one, with prevalence approaching 15% of the pediatric population for some groups[54])
of humans fail to develop that tolerance despite exposure to the same allergens that others are
tolerant to. Elucidation of the mechanisms that drive tolerance in animal models of asthma is
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critically important to identify targetable mechanisms that could promote tolerance in human
asthma sufferers. Our work[31; 32; 41] as well as that of others[30] has suggested that regulatory
T cells (Tregs) are critically important for the generation and maintenance of tolerance to inhaled
allergens. In humans, Tregs have been shown to be functionally impaired in a number of allergic
diseases[262], and a growing body of evidence has revealed that many human asthmatics have
decreased numbers of Tregs, diminished suppressive capacity in those Tregs that are present,
or a combination thereof[24; 37; 38; 263].
One of the forces driving tolerance-promoting Tregs is the host microbiome. Multiple microbial
populations have been shown to drive the formation of inducible Tregs (iTregs), particularly in gutassociated tissues[124; 125; 127; 131]. Despite the fact that these Tregs are generated in the
gut, they can have protective affects in a number of tissues, and some have reported that it is
these iTregs, rather than thymically-derived Tregs, that are most important for suppression of
allergic inflammation in the lung[35].

The microbiome is shaped by its exposures, and these

exposures influence its ability to regulate the immune system, including through Tregs. Several
studies have shown that products produced by gut microorganisms as they ingest the food that
we eat, particularly production of short-chain fatty acids (SCFAs) from dietary fiber, can resolve
experimental asthma in the lung through induction of Tregs[133; 134].
Furthermore, allergens may themselves have a role to play. House dust mite (HDM), one of the
most common human allergens, is highly complex, consisting of products from the mite itself as
well as associated bacterial and fungal components[32]. At least one study has shown that certain
kinds of HDM and the house dust they dwell in can contain protective microorganisms that
colonize the gut of exposed animals and protect against experimental asthma[139]. However,
the HDM commonly utilized in our laboratory and others is a standardized extract from Greer
Laboratories, not a sample obtained from the complex environment of a home. Almost no
information exists on the impact of this standardized HDM extract on the microbiome despite its
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wide use. A single recent report described changes induced by HDM exposure that depended
on the age of the animal[264]. However, this report evaluated changes in the microbiome after
just three intranasal sensitizations and subsequent challenge with HDM 21 days later. Evidence
for the effect of prolonged HDM exposure on the microbiome remains to be determined. For this
investigation, we hypothesized that exposure to HDM would promote the development of a
regulatory microbiome, and that this regulatory microbiome would promote the suppression of
AAD through accumulation of organisms known to induce Tregs. In the present chapter, we
explore this hypothesis through assessments of the fecal microbiome across our model of HDMinduced AAD.

Results
Sample Numbers and Groups
The fecal microbiome was assessed in three independent groups of animals subjected to our
HDM model of asthma, one each for the years 2013-2015. One group (35) was assessed at each
stage of the model (pre-intranasals, or naïve; 2; 5; and 11 weeks) for HDM as well as PBSexposed mice. A second group (27) was assessed at each stage of the model in HDM-exposed
animals alone.

The final group was assessed at the naïve and 11 week HDM exposure

timepoints. At least twenty HDM-exposed animals were assessed at each timepoint of the model.
Details of sample numbers by group and timepoint may be found in Table 1. These numbers
represent the samples analyzed using QIIME in Figures 8 and 9.

HDM Exposure Does Not Consistently Alter the Composition of the Fecal
Microbiome
Analysis of the composition of the microbiome using QIIME revealed that the three groups of
HDM-exposed mice experience changes in the fecal microbiome that differ between groups but
tended to be similar to time-matched PBS controls (Figure 8). All naïve samples began with a
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similar microbial community dominated by a group of organisms only classifiable as order
Clostridales and the family S24-7. Family S24-7 have been previously shown to represent a large
portion of the mouse fecal microbiome and represent an as-yet uncultured and poorly-described
group of Bacteroidetes[265; 266].

Over time, all samples saw the proportion of genus

Akkermansia increase from nearly undetectable in naïve animals (with the sole exception of group
27) to upwards of 20-40% of all organisms by eleven weeks of either PBS or HDM exposure. The
proportion unclassifiable order Clostridales tended to decrease with time across all groups, as did
the proportion of organisms within the family S24-7, although the latter organisms continued to
make up the single most abundant group of organisms for all timepoints and exposures. In all
groups and treatments, the proportion of genus Lactobacillus tended to decreases and the
proportion of family Rickenellaceae tended to increase, although the abundance of the latter
remained below 10% of all organisms across groups and treatments.
Those differences between PBS- and HDM-exposed animals which did exist were not consistent
between experimental groups. In group 35, HDM-exposure was associated with increases in
organisms of genus Blautia, genus Parabacteroides, order RF32 (a Proteobacteria), and genus
Bacteroides as compared to PBS-exposed animals. Indeed, Blautia and RF32 were essentially
present only in HDM-exposed animals. Contrastingly, an unidentified group of organisms within
the family Ruminococcaceae were only present in PBS-exposed animals after eleven weeks of
exposure. However, both group 6 and group 27 exhibited no appreciable population of Blautia,
RF32, Parabacteroides, or Bacteroides. Furthermore, these two groups had members of the
unidentified Ruminococcaceae in both HDM- and PBS-exposed populations. For group 6, HDM
exposure was associated with no distinct populations of organisms when compared to PBS
controls, although the proportions of the unidentified group of order Clostridales and unidentified
organisms of family Lachnospiraceae were different between the HDM and PBS, the former being
more abundant and the latter less abundant in HDM-exposed animals as compared to PBS.
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Group 27 has no time-matched PBS control, but its final composition was similar to that of group
6’s HDM-exposed animals save for a higher proportion of genus Allobaculum.

HDM-Induced Fecal Microbiome Changes Are Inconsistent and Often Similar to
PBS-Induced Changes
Principle coordinate analysis (PCoA) of the unweighted UniFrac distances between the groups
confirmed the qualitative taxonomic comparisons seen in Figure 8. Comparisons of groups 6
(Figure 9, lower left), 27 (Figure 9, lower right), and 35 (Figure 9, upper right) revealed that all
naïve samples tended to be similar at the start of the experiments, residing in the lower right of
the coordinates plot. Additionally, all groups shifted in a similar manner over time, moving from
the lower right of the coordinate plot up and to the left, with the majority of the change seen along
principle coordinate 2. Group 35 differed the most from the other two, with eleven week and some
five week HDM samples occupying a distinct position in the lower left from all other samples.
Eleven week samples from groups 6 and 27 changed in a similar manner to each other but distinct
from group 35. PBS-exposed animals in groups 35 and 6 shifted in a similar manner to timematched HDM-exposed animals. Only animals in group 35 differed appreciably along both
principle coordinates after eleven weeks of PBS or HDM.

Inter-Group Variability Drives Fecal Microbiome Changes Rather Than HDM
Exposure
To assess the importance of individual taxa, including those whose abundance was below the 1%
threshold for graphical depiction described in the Materials and Methods, LEfSe was utilized to
identify taxa which differed between treatment groups (Figure 10A).

Initial LEfSe analysis

evaluating differences between treatment groups (the class, e.g. 11 week HDM vs 11 week PBS)
initially identified several dozen taxa, including several known to have immunomodulatory effects
(Figure 10A, e.g. genus Lactobacillus and genus Clostridium). However, secondary analysis with
groups (the subclass, e.g. Group 35 vs Group 27) revealed only a single taxa with differential
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representation between treatment groups, family Clostridaceae, genus Clostridium which was
overrepresented in naïve animals (Figure 10B). This taxa is present in most naïve animals (Figure
11) but not present in all but a handful of animals by 11 weeks, suggesting that its disappearance
is a result of normal changes with aging rather than treatment effect.

HDM Exposure Does Not Significantly Affect Microbial Diversity
Diversity of the microbiome is an additional metric which may influence host health by itself.
Analysis of Simpson’s Diversity Index across the 11 week experiment (a metric where higher
numbers correspond to higher diversity) shows that diversity tends to increase as time passes
(Figure 12A) but that there is no significant difference between HDM and PBS treatment by 11
weeks of exposure (Figure 12B).

Discussion
The present investigations suggest that intranasal exposure to HDM extract does not have a
consistently differential impact on the composition of the fecal microbiome. These data have
important implications related to tolerance research as well as the results of several other seminal
asthma microbiome studies.
One potential contributing factor to the differences we noted between the groups exposed to HDM
concerns the housing facility.

The UConn Health Center for Comparative Medicine (CCM)

underwent extensive renovations in 2014, with all animals moved from the old facility, which had
not been significantly altered in the 37 years since its construction, to a new, cleaner space in the
basement. This move occurred in January of 2014. Animals remained in the basement facility
until February of 2015, when they were moved back to the newly-renovated original facility. Thus,
the 2013 group experienced the original, dirtier facility; the 2014 group experienced the clean,
basement facility; and the 2015 group experienced the clean, renovated facility, with no overlap
in facilities for any group. This raises the possibility that the differences seen in 2013 were a
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consequence of the facility, and that both cleaner environments in 2014 and 2015 did not harbor
or promote the microorganisms that defined HDM exposure in 2013 (e.g. genus Blautia). This
would also suggest a reason why the 2014 and 2015 groups were similar in composition, as both
experienced new, clean facilities.
This facility effect is not unprecedented. One group at Emory University has undertaken several
studies of TLR5 knockout mice[267; 268]. In the first instance, they noted that most mice exhibited
a phenotype consisting of severe intestinal inflammation and colitis[267]. In the second, they
noted that only some animals exhibited colitis, while the majority had mild inflammation but
pronounced obesity. Through careful re-derivation in mothers from the source facility (the Jackson
Laboratory), they discovered that the microbiome of their facility tended to promote colitis in the
absence of TLR5, while the microbiome of the Jackson Laboratory tended to promote milder
inflammation and obesity[268]. Clearly, the environment to which laboratory animals are exposed
can have an enormous impact on the results of microbiome studies, and it is critical for important
findings to be replicated in multiple facilities. Indeed, if a result does not replicate, this should be
cause for excitement, as the differences in the microbiome between facilities could hold clues to
organisms that could aggravate or alleviate the biological process under study.
A second possibility concerns the effect of cages. Mice housed in separate cages, even when
they originated in the same facility, may diverge with time. This concern is one which has become
increasingly recognized by microbiome researchers[269], particularly after reassessment of a
series of studies in knockout mice. Initial reports of mice deficient in the immune signaling adaptor
MyD88[270] as well as various TLRs[268] reported that these genotype alterations alone could
drive changes in the microbiome. However, subsequent assessment by an independent group
revealed that these effects were likely due more to the influence of the maternal microbiome and
cage divergence following long periods of isolation from the original source environment[271].
Such cage effects, particularly over the long timecourse of the present study, could be the driving
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force behind the differences seen. One argument against this, particularly for the differences
seen in 2013, is that multiple cages were utilized (four which received HDM and two which
received PBS) and the effect of HDM exposure did not depend on source cage.
That changes did not depend on cage, and that changes were similar between groups, particularly
in 2014 and 2015, suggests a simpler reason for the shifts observed: normal evolution of the
microbiome with age. We know that the microbiome can change with age, particularly early in
life. Assessment of the developing human microbiome revealed that its composition changes
rapidly in the first few years of life[109]. In mice, analysis of older animals has shown that
significant shifts continue even up to 800 days of age[272]. In fact, the sole existing study
assessing the impact of HDM exposure on the microbiome found many changes, but most of
these could be attributed to age or to HDM and age rather than to HDM alone[264]. An additional
view on the matter comes from an unlikely source: the control animals in a study of early-life
antibiotic (ABS) use by Martin Blaser’s group[273]. The ABX-exposed group shifted much in the
first 30 weeks of life, as expected, but so too did the control group. Interestingly, some of the
changes seen in the control mice were analogous to those in our groups, including the decline of
Lactobacillus, a shift perhaps driven by the cessation of nursing after weaning. The fact that the
sole taxa found to differ by LEfSe was found in naïve animals and not in animals after 11 weeks
supports this theory.
One study for which the present work has great relevance is the investigation by Fujimura and
colleagues that demonstrated that a particular bacteria in the house dust of homes with dogs,
Lactobacillus johnsonii, was protective against experimental asthma in laboratory mice[139]. In
the study, they describe obtaining house dust from the homes of dog owners and homes without
dogs, and that the aforementioned bacteria was only found in homes with dogs.

However, no

mention is made of the diversity of the homes (or even the number) from which the house dust
was obtained. Suppose that replication of this study across the homes of dozens or hundreds of
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dog owners in different regions reported that only some homes with dogs harbored the protective
L. johnsonii? Suppose, too, that the homes which provided protection harbored house dust with
different microbial communities?

Rather than being a disappointment, this could explain a

puzzling conflict in the literature concerning pet ownership and asthma. A number of studies have
reported that growing up in a home with a dog is protective against the development of
asthma[274; 275], while others have found no significant protective effect[276; 277] or even a
tendency to increase risk of developing asthma[278]. Similarly, studies of cat ownership have
reported asthma protection[276], asthma promotion[279], or no effect at all[277]. Studies of pet
ownership in general have been no less definitive, with some reporting increased risk of
asthma[280] and others no association at al[281]. What if these discrepancies were driven by the
environmental microbiome of the pets in question?

Perhaps some breeds carry unique

microorganisms that can aggravate or alleviate asthma symptoms. The present work would
certainly seem to suggest that relying on only one or a few tests of HDM exposure is insufficient
to provide definitive evidence for protection or lack thereof.
A final important consideration concerning HDM exposure is one of microbiome location; namely,
have we selected the most appropriate one to analyze?

Given the intranasal route of

administration, the lung microbiome might have been a more appropriate site to study. It is
possible that the lack of consistent, HDM-specific microbiome changes in the gut belies changes
in the lung that can be attributed to HDM and HDM alone. Some recent work has suggested that
inhalational tolerance (and pulmonary immune responses in general) requires a healthy
microbiome to develop[179]. However, this and other work are severely limited by a general lack
of knowledge concerning what a health or normal lung microbiome even is[171; 172]. Moreover,
many specific immune-microbiome relationships remain unclear within the lungs. Do Tregs
generated in the mucosa of the lung have the same relationship to the microbiome as those in
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the gut, where much is known? Do dendritic cells in the lung sense the microbiome in the same
way as those in the gut? Many of these questions remain to be answered.
The present study has uncovered a number of important questions but has provided strong
support for the answer to another, namely that inhalational HDM exposure does not produce
consistent changes in the gut microbiome, including no consistent induction of a organisms known
to promote immune regulation. This suggests that a simple, organismal answer to the question
of how (or if) the gut microbiome influences development of inhalational tolerance to HDM is not
likely forthcoming, but it does not rule out other regulatory gut microbiome functions changing with
HDM exposure (e.g. production of pro-regulatory products to differing degrees despite
inconsistent community composition changes) or changes in the microbiome of an entirely distinct
compartment (e.g. the lung). A final question concerns the impact of oral (swallowed) exposure
to HDM in the process of intranasal administration. This will be addressed in Appendix A of this
dissertation.
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Figures
Table 1: Sample Numbers by Timepoint and Group
NAIVE

2 WEEK
HDM

2 WEEK
PBS

5 WEEK
HDM

5 WEEK
PBS

11 WEEK
HDM

11 WEEK
PBS

GROUP
35 (2013)

11

12

6

11

6

9

3

GROUP
27 (2014)

28

20

GROUP 6
(2015)

8

TOTAL

47

32

21

6

32

Table 1. Sample Numbers by Timepoint and Group.

7

6

8

6

24

9

Sample numbers represent samples

analyzed using QIIME after rarefaction to 10,000 reads. Samples with fewer than 10,000 reads
after quality filtering were not included in analyses. Figures 8-12 represent analyses of the
samples in this table.
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Figure 8: HDM Exposure Does Not Consistently Alter the Fecal
Microbiome

Figure 8. HDM Exposure Does Not Consistently Alter the Fecal Microbiome. QIIME was used to
pick OTUs and analyze samples from mice that had received PBS or HDM gavage. OTUs picked
at the 97% similarity level are represented as bars in (A). Bars represent the average abundance
of each OTU. In (A), o__ refers to Order, f__ refers to Family, and g__ refers to Genus. OTUs
lacking a lower classification (e.g. an organism identified at the Order level but not the Family or
Genus level) refers to an unidentified OTU within that level, not all organisms at that level. For
example, the OTU identified as Order Clostridales does not represent all Clostridales, merely one
Clostridales at the 97% similarity level that is not classified in GreenGenes below the Order level.
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Not all groups contain samples from all timepoints. Refer to Table 1 for sample sizes by group
and timepoint.
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Figure 9: HDM-Induced Fecal Microbiome Changes Are Inconsistent &
Similar to PBS
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Figure 9. HDM-Induced Fecal Microbiome Changes Are Inconsistent & Similar to PBS. PCoA
was performed on the distance matrix of the unweighted UniFrac distances and the two largest
principal coordinates represented. Samples from each group were separated out from the same
PCoA. Black arrows represent the direction of change from Naive samples to 11 Week HDM
samples. Not all groups contain samples from all timepoints. Refer to Table 1 for sample sizes
by group and timepoint.
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Figure 10: Inter-Group Variability Drives Fecal Microbiome Changes
Rather Than HDM Exposure
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Figure 10. Inter-Group Variability Drives Fecal Microbiome Changes Rather Than HDM
Exposure. Linear Discriminant Analysis with Effect Size (LEfSe) was performed on (A) the
taxonomy table of abundances for all taxa based on treatment types as the class – naïve, 11
week HDM, or 11 week PBX – or (B) based on treatment types as the class and groups as the
subclass – Group 35, Group 27, and Group 6. Blue bars represent taxa which are associated
with naïve animals, green bars represent taxa associated with 11 weeks of PBS treatment, and
red bars represent taxa associated with 11 weeks of HDM treatment. Refer to Table 1 for sample
sizes by group and timepoint.
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Figure 11: Family Clostridaceae, Genus Clostridia Varies with Age
Rather than Treatment

Figure 11. Family Clostridaceae, Genus Clostridia Varies with Age Rather than Treatment.
Percent of all organisms represented by Clostridaceae Clostridia in all samples by timepoint.
Numbers represent percents (e.g. 0.1 is 0.1%, not 10%). Symbols represent individual animals
at the specified timepoints. Data represent the mean ± the SEM. Black lines separate naïve
timepoints (leftmost five columns), 11 week PBS timepoints (middle two columns), and 11 week
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HDM timepoints (rightmost three columns). Refer to Table 1 for sample sizes by group and
timepoint.
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Figure 12: HDM Exposure Does Not Produce Significantly Different
Gut Microbiome Diversity
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Figure 12. HDM Exposure Does Not Produce Significantly Different Gut Microbiome Diversity.
Diversity of the gut microbiome represented by Simpson’s Diversity Index plotted across the 11
week experiment (A) and at 11 weeks (B). In (A), not all experimental groups have samples at
all timepoints. In (B), data points represent individual animals in all three experimental groups,
n=23 for HDM and 9 for PBS. Data represent the mean ± the SEM. Analyzed using nonparametric Mann-Whitney Test. Refer to Table 1 for sample sizes by group and timepoint. ns,
not significant.
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CHAPTER 4
EARLY-LIFE ANTIBIOTIC EXPOSURE INCREASES THE SEVERITY
OF HDM-INDUCED AAD
Introduction
Asthma is an inflammatory disease of the airways that arises from an inappropriate immune
response to innocuous environmental allergens[2; 4]. The prevalence of the disease has nearly
doubled since the 1980s and today stands at nearly 10% of children[10; 50; 282]. In some
populations, such as African Americans, prevalence is higher still, approaching nearly 15% of
children[54]. The sharp increase in prevalence has been termed the “asthma epidemic”[50], and
while the most recent data suggest that overall asthma prevalence may be stabilizing, it continues
to rise in some populations, including adolescents and the poor[54]. Whether prevalence is
stabilizing or still rising, this epidemic is a costly one, for asthma carries a high morbidity burden
for patients. Indeed, the disease has long been the third leading cause of hospitalization in
children[55].
One of the most important questions concerning the asthma epidemic has been determining what
factors may underlie rising prevalence. One important complicating factor is that the lack of a
gold-standard test for asthma[9] or even one single definition of asthma makes interpretation of
asthma prevalence challenging[10]. Despite this, the evidence is overwhelming that prevalence
has increased, even if the magnitude of the increase is not precisely measurable[50; 54; 282].
One factor which has been extensively investigated is the role of early childhood exposure to
antibiotics (ABX) and the effect of ABX on the host microbiome. Over 20 clinical studies have
shown that ABX, particularly in the first year of life, significantly increases the odds of developing
asthma later in childhood[112–116].
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Despite this clear association it remains just that: an association. Understanding the mechanisms
behind the association is critical to the development of therapies that could halt the development
of asthma or, perhaps, provide a cure for this as-yet incurable condition.

Dissecting such

mechanisms, particularly when they are related to the microbiome and the immune system, is
complex, if not impossible, in human subjects. Recognizing this, multiple groups have explored
the role of antibiotics on development of asthma using laboratory mice, and these studies have
been unified in their message: ABX worsen subsequent experimental asthma and alter the
immune response to asthma-inducing allergens[117; 118; 145; 229; 283–286].
However, these studies have important limitations when it comes to comparisons with human
asthma and ABX. Several of these studies utilized germ free (GF) mice, where no microbial
exposure occurs[284; 286], an extreme version of early-life ABX exposure. While GF mice are
undeniably a useful model to assess how the microbiome affects the host immune system in the
most extreme manner, no human child grows up in a germ free state, and the clinical relevance
of the significant immune disturbances recognized in GF animals[287] remains unclear. Similarly,
several investigations have focused on antibiotic exposure from prior to birth until later in life,
which may be more akin to the GF mouse than human childhood ABX treatment[118; 229].
Finally, two reports exposed mice to ABX for prolonged periods of at least four weeks[145; 285],
much longer than a typical childhood antibiotic course[288].
These studies have provided important insights into how antibiotic exposure may influence the
developing immune system and susceptibility to asthma, but development of a more clinicallyrelevant animal model of early childhood antibiotic exposure would be of great benefit in
determining which factors are behind the increased susceptibility to asthma seen in human
children. In the present study, we hypothesized that exposing laboratory mice to ABX in a manner
similar to that of human children (i.e. brief, but repeated, exposures) would increase the severity
of house dust mite (HDM)-induced allergic airway disease (AAD) later in life.
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Results
Antibiotic exposure increased the severity of HDM-induced AAD
Mice developed profound airway leukocytosis (Figure 13A) following HDM exposure, in
agreement with our previously published results for the model[32]. Exposure to HDM and the
cocktail of four ABX (HDM + Antibiotic Mix) resulted in three-fold higher BAL leukocytosis (Figure
13A) as compared to HDM alone. By contrast, leukocyte counts in the BAL of mice exposed to
HDM and amoxicillin (HDM + Amoxicillin) were not significantly elevated over HDM or HDM +
Antibiotic Mix animals. All leukocyte counts were many-fold higher than the level seen in naïve
mice not exposed to HDM or ABX, represented by a dotted line in Figure 13A.
As expected based on our previous results[32], exposure to HDM resulted in airway eosinophilia
(Figure 13B), with over 20% of BAL leukocytes being eosinophils in HDM-exposed animals. HDM
+ Antibiotic Mix animals had two-fold higher relative eosinophilia as compared to HDM animals
(43% vs 20%, p < 0.01) and HDM + Amoxicillin animals (43% vs 28%, p < 0.05). HDM +
Amoxicillin animals did not significantly differ in eosinophil proportion from HDM animals.
Similarly, total eosinophil numbers (Figure 13C) were nearly five-fold higher in HDM + Antibiotic
Mix animals as compared to HDM exposed animals (2.3 x 106 vs 4.6 x 105 eosinophils, p < 0.05).
HDM + Amoxicillin mice fell between HDM and HDM + Antibiotic Mix mice and did not significantly
differ in eosinophil numbers from either group. In all cases, the relative increase in eosinophils
was at the expense of the relative proportion of macrophages, which make up more than 90% of
the cells in a naïve mouse airway[32].

Antibiotic exposure increased the severity of tissue inflammation in the lungs
HDM exposure led to evidence of perivascular and peribronchial inflammation in the lungs (Figure
14A-C), particularly clusters of inflammatory cells surrounding the airways and vasculature and
airway smooth muscle (ASM) hyperplasia and hypertrophy around the small airways. Blinded
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comparison of the inflammation and ASM remodeling revealed that HDM + Antibiotic Mix mice
harbored more severe histopathologic changes than either HDM or HDM + Amoxicillin mice, both
of whom were not significantly different from each other (Figure 14G). Pathology scores for HDM
mice were similar to those noted in our previous description of the model[32]. By contrast,
evaluation of mucus production (Figure 14D-F) showed no significant differences in mucus scores
between any two groups (Figure 14H).

Serum HDM-specific IgE is elevated in mice treated with antibiotics early in life
A hallmark of allergic asthma and AAD is the appearance of allergen-specific IgE in the serum.
This has been demonstrated in multiple models of allergic asthma in mice, including
ovalbumin[222] and HDM[32]. In agreement with our previous model data, serum HDM-specific
IgE appeared following HDM exposure (in naïve animals, it is virtually undetectable[32]).
However, HDM + Antibiotic Mix animals had significantly higher levels of HDM-specific IgE than
HDM animals (Figure 15). HDM + Amoxicillin animals did not significantly differ from either group,
although there was a trend toward higher levels of HDM-specific IgE as compared to HDM animals
(p = 0.078).

Airway hyper-reactivity (AHR) was significantly elevated in antibiotic-treated
mice
Exposure to HDM induces ASM remodeling that results in AHR and bronchoconstriction in
response to allergens and agents such as the non-selective muscarinic receptor agonist
methacholine[32]. This bronchoconstriction is a factor in the characteristic chest tightness and
wheeze seen in asthmatics[4].

Experimental assessment of respiratory function using the

flexiVent system revealed that HDM + Antibiotic Mix animals had significantly higher increases in
total respiratory system resistance (Rrs) in response to mechacholine challenge as compared to
HDM animals (significant effect of the interaction of methacholine dose with treatment, 2-way
ANOVA, p < 0.05, Figure 16A). These differences were most pronounced at higher doses of
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aerosolized methacholine, particularly 300 mg/mL (p < 0.01, HDM vs HDM + Antibiotic Mix, Figure
16A). Furthermore, comparison of the area under the curve (AUC) of the Rrs for HDM vs HDM +
Antibiotic Mix animals showed significantly higher AUC for those animals exposed to both HDM
and Antibiotic Mix as compared to HDM alone (3.84 vs 5.168, p < 0.05, HDM vs HDM + Antibiotic
Mix, Figure 16B).

Antibiotic exposure reduced the proportion of regulatory T cells in the lungdraining (hilar) lymph node (HLN)
Our laboratory[31; 32; 41] and others[263; 289] have shown that Foxp3+ regulatory T Cells
(Tregs) play a critical role in the control of asthma and allergic disease. Furthermore, previous
work from our lab has shown that Tregs increase and orchestrate the development of tolerance
and disease suppression to both inhaled ovalbumin[31; 41] and HDM[32] from within the in the
lung-draining, or hilar, lymph node (HLN). Assessing the frequency of Foxp3+ Tregs in the HLN
revealed that HDM + Antibiotic Mix mice had significantly lower proportions of Tregs as a percent
of total CD4+ T Cells than HDM mice (8.93% vs 11.1%, p < 0.05, Figure 17). HDM + Amoxicillin
mice fell between the two groups and did not significantly differ from either HDM or HDM +
Antibiotic Mix.

Antibiotic exposure reduced the diversity of the fecal microbiome
We have known for over half a century that antibiotics rapidly alter the composition of the gut
microbiome[290], and more recent studies have shown the specific microbial community changes
that result from antibiotic administration in both humans[109] and laboratory animals[111],
including a loss of many bacterial genuses. A similar pattern was seen between in the present
study. Antibiotic Mix treatment resulted in a sharp reduction in phylum Bacteroidetes, particularly
order Bacteroidales, which was nearly absent in Antibiotic Mix-treated animals as compared to
No Treatment animals (Figure 18A). Phylum Firmicutes remained present after Antibiotic Mix
treatment but with a very different composition. Class Clostridia, particularly organisms of order
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Clostridiales such as family Lachnospiraceae, are much reduced when compared to No
Treatment animals, and organisms of the Firmicutes order Turicibacterales and Lactobacillales
(genus Turcibacter and Enterococcus, respectively) dominate. The latter two genuses are nearly
absent in No Treatment animals.
Following HDM exposure, animals not treated with antibiotics (denoted HDM in Figure 18) have
similar community composition to No Treatment animals, dominated by Bacteroidales and
Clostridales, although organisms of the clostridial family Lachnospiraceae are reduced and
organisms of the Firmicutes genus Allobactum appear. However, in Antibiotic Mix mice, five
weeks of HDM treatment and no antibiotic exposure (HDM + Antibiotic Mix) witnessed some
recovery of the microbial community, but not to the level of either the No Treatment or HDM
animals. Phylum Bacteroidetes reappears, but its lower-level composition differs. Some order
Bacteroidales organisms returned, but nearly half of Bacteroidetes consisted of organisms of the
genus Parabacteroides, an organism almost absent from either No Treatment or HDM animals.
Nearly half of the organisms present were of the phylum Verrucomicrobia, genus Akkermansia,
an organism making up less than 6% of the microbiome in both No Treatment and HDM animals.
Principle coordinate analysis (PCoA) of the unweighted UniFrac distances confirmed these
changes (Figure 18B).

No Treatment and HDM animals were virtually indistinguishable by

analysis of PC1 and PC2 (which together represented over 50% of the variance within the
samples). Both differed considerably from either Antibiotic Mix or HDM + Antibiotic Mix animals
along PC1, which accounted for most of the variance between the samples (nearly 43%), and
also differed considerably along PC2, which accounted for just over 19% of the variance amongst
samples. However, this latter difference was not the same between Antibiotic Mix and HDM +
Antibiotic Mix, as the two differed from each other along PC2.
In addition to assessment of microbiome diversity by examining community composition (Figure
18A), it is possible to calculate the diversity of the community using one of many indices, such as
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the Shannon diversity index[291]. Assessment of the alpha diversity (within-sample diversity)
revealed that the Shannon diversity index significantly differed between HDM and HDM +
Antibiotic Mix animals at the time of sacrifice (Figure 18C). The mean diversity of the fecal
microbiome of HDM mice was a third higher than HDM + Antibiotic Mix (0.954 vs 0.747, p < 0.01).
To separate the effects of antibiotic exposure from HDM exposure on the composition of the
microbiome, LEfSe was utilized to identify taxonomic “biomarkers” linked to antibiotic treatment
and not confounded by HDM exposure (Figure 19A). The identified taxa lost with antibiotic
treatment match those described in Figure 18 and include many, such as Lachnospiraceae and
Clostridium, with known immunologic activity. Those taxa which increase in proportion with
antibiotic treatment include organisms, such as genus Enterococcus, with known pathogenic
properties. Further analysis to isolate those organisms whose effects are due to HDM and not
ABX (Figure 19B) shows several organisms, including those with pro-regulatory properties such
as genus Blautia, more represented in HDM-treated animals. However, the absence or nearabsence of these organisms in the ABX treated and HDM exposed animals (Figure 18A) suggests
this effect may be driven solely by the non-ABX treated, HDM-exposed animals.

Decreased diversity of the fecal microbiome directly correlates with the
proportion of Tregs in the HLN
The diversity of the fecal microbiome directly correlated with elements of immune regulation.
Plotting the Shannon diversity index against the proportion of Foxp3+ Tregs in the HLN (Figure
20) for both HDM and HDM + Antibiotic Mix mice revealed that there was a positive correlation
between microbiome diversity and the proportion of Tregs (Spearman r=0.7109, 0 < 0.01). As
diversity increased, so too did Treg proportions.
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Discussion
We are not the first to explore alternatives to commonly-used ABX treatment regimens in
laboratory mice. Martin Blaser and his group have shown that brief, repeated administration of
ABX early in life can induce dramatic changes in metabolic activity that persist to a minimum of
six months of age[228]. However, while this report contained many details on metabolic changes
wrought by ABX exposure, it did not assess how such ABX may affect immune function. The
present study demonstrates that brief, repeated ABX exposures can worsen subsequent
experimental asthma, confirming the efforts of others who have administered long-term ABX
regimens[145; 285] or evaluated ABX treatment from before birth until later in development[118;
229] and found the same.
The present study also adds to two reports that paired brief ABX treatment with secondary fungal
spore inoculation[117; 283]. In both, the combination of spores and ABX significantly enhanced
the severity of subsequent experimental asthma. This, paired with data that an environment with
significant fungal exposure is related to the development of asthma[292], would seem to indicate
that brief ABX exposure and fundal inoculation is a good model of pediatric ABX exposure and
asthma. However, the same report linking environmental fungal exposure to asthma also found
less than 12% of asthmatics were sensitized to the fungi in question[292], suggesting that fungal
exposure may promote the development of asthma in conjunction with early-life ABX exposure
but that it does not account for all the childhood asthma risk ABX carries.
The link between early life microbiome diversity and asthma that we report, and the association
of said diversity with Treg proportions, add mechanistic explanation to reports linking low early
life diversity of the gut microbiome[95] and the environmental microbiome[96] to subsequent
asthma and allergy development. However, not all such reports are in agreement. One recent
analysis of an ongoing study of children in Canada found no link between diversity and the
development of asthma, although they did report that the loss of a number of genera was
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associated with asthma severity[97]. There is one important difference between the studies which
may complicate the comparison. This report examined children at ages two or three[97], while
the other two studies evaluated asthma at age seven[95; 96]. In an early study of children in day
care, it was noted that day care was associated with increased wheeze in the toddler years but
reduced asthma by age six[77]. We may need to await further results from the Canadian cohort
before final judgement on the relevance of microbiome diversity to asthma development.
Interestingly, one group of organisms whose reduction was association with asthma development
in the Canadian study were those of the genus Lachnospira[97], falling within the family
Lachnospiraceae, one of the families that was nearly eliminated by ABX treatment in the present
study, although its proportions subsequently recovered somewhat. Members of this genus could
have a common effect between humans and mice, and are worth exploring for potential probiotic
use. Indeed, these organisms have been linked to Treg induction in mice, as members of the
family Lachnospiraceae fall within the clostridial clusters known to induce Tregs through
fermentation of dietary fiber and production of short-chain fatty acids[131]. Their loss in this study
may be one of the factors behind the decrease in Tregs seen, even five weeks after the cessation
of ABX therapy.
Considering probiotics, the present study may provide some insight into the failure of many
probiotics to translate from benefits in mice to protection in humans. Multiple clinical trials have
failed to demonstrate any benefit from the administration of probiotics[189] despite abundant
evidence of their benefit in laboratory mice[183–188]. It may be that the addition of one or even
a few organisms is insufficient to correct a profound loss of microbiome diversity in humans, and
that only therapies which meaningfully impact diversity will have an effect on asthma
susceptibility.

Fecal microbiome transplantation (FMT), which provides an entire, diverse

microbiome to the recipient, may be the means to overcome the loss of diversity seen with ABX
administration. FMT is already available in capsule form for the treatment of Clostridium difficile
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infection[192], and a future course of ABX for a childhood infection could be accompanied by an
FMT pill to correct the disruption of the microbiome once the ABX had eradicated the pathogenic
organism.
However, despite the evidence of the dangers of ABX use in childhood with respect to asthma
development, it is important to remember the critical benefits of the drug class. Diseases from
acute rheumatic fever to bacterial meningitis killed millions of children prior to the introduction of
ABX[293], and to reduce ABX use indiscriminately in an effort to reduce asthma prevalence would
be foolish and ethically unsound. However, there are many steps that can be taken to reduce
unnecessary ABX use without endangering children. Consider the common childhood ailment
otitis media, otherwise known as an ear infection. ABX are commonly administered to treat otitis
media, but multiple analyses (summarized in a meta-analysis of 63 such studies[294]) found that
the majority of cases spontaneously resolved without the need for any intervention. Better
targeting of ABX to only those children at greatest need of pharmacological support could reduce
the risk of developing asthma that unnecessary ABX use carries.
An important obstacle to such efforts is the perceived need to prescribe ABX seen by many
physicians. Confronted with limited time to see each patient and the demand to increase patient
satisfaction, many physicians simply prescribe ABX even when they suspect it is unwarranted,
assuming that little harm will come of the misdeed[295]. Fortunately, recent data suggest that
physicians can both rationally prescribe ABX and increase patient satisfaction and outcomes in
the same blow. In one recent randomized controlled trial evaluating uncomplicated respiratory
infections, simply providing an ABX prescription immediately (but instructing patients not to fill it
unless symptoms persisted) or telling patients to return to the clinic for an ABX prescription if they
continued to feel unwell or worsen was sufficient to reduce the duration of symptoms when
compared to patients not given a prescription at all[201]. In this way, ABX prescription was
reduced without adversely affecting clinical outcomes. A true “win-win” scenario for any clinician.
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The case of amoxicillin in the present study is an intriguing one. For nearly all parameters,
including HLN Treg proportions, amoxicillin-treated mice fell somewhere between those mice
exposed to HDM alone and those mice exposed to HDM and the mix of four ABX. While there
was no significant increase in disease severity, this broad tendency to higher disease severity
and lower Tregs could combine with other factors to influence disease. Asthma arises from a
fundamental imbalance between regulatory and inflammatory responses of the immune
system[296]. While amoxicillin exposure may not provide sufficient impetus to shift the balance
on its own, it could remove just enough from the regulatory side to increase susceptibility to or
increase severity of asthma in the presence of other contributing factors, such as a lack of
exposure to dirty environments when young (e.g. a child in a clean, suburban house as compared
to one living on a farm[83]) or one of the known genetic risk factors for asthma such as variations
in the gene encoding thymic stromal lymphopoietin[297]. Early-life amoxicillin use could be one
factor that initiates the so-called “atopic march” that characterizes so many children with asthma,
allergic rhinitis, and other childhood allergic diseases[298], but it may require help to meaningfully
increase the risk of developing the disease.
One point of concern with the choice of the cocktail of four ABX is the lack of clinical relevance of
that particular combination. Some severe diseases can warrant such broad-spectrum ABX
cocktails, such as necrotizing enterocolitis and other complicated intra-abdominal infections[299],
but most children will not be routinely exposed to such treatment early in life (if ever). While the
use of this regimen is far from ideal, the use of a series of three short doses rather than weeks or
more of similar cocktails is closer to the clinical reality than previous studies have been. An
important avenue for future investigation would be to determine if a subset of this cocktail was
sufficient to increase disease severity (e.g. vancomycin alone or neomycin and metronidazole
together). An important consideration is that whether an antibiotic increases the severity of
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disease can be dependent on the disease as much as on the antibiotic[118; 230], so results found
for asthma may have only partial relevance for other diseases.
To conclude, the present study describes a clinically-relevant model of the effects of early-life
ABX exposure on the subsequent severity of experimental asthma later in life. Exposure to a
cocktail of four ABX increased the severity of all parameters of experimental asthma, including
BAL eosinophilia, AHR, and serum allergen-specific IgE levels. Increased disease severity was
accompanied by a loss of Tregs, known moderators of the allergic inflammatory response. ABX
reduced the diversity of the fecal microbiome in a sustained manner, and this reduction in diversity
correlated with the loss of Tregs seen with ABX administration, providing a mechanism behind
clinical studies that have linked early-life microbiome diversity with subsequent asthma
development in human children.
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Figures
Figure 13: Early-Life Antibiotic Exposure Increases the Severity of
Experimental Asthma

Figure 13. Early-Life Antibiotic Exposure Increases the Severity of Experimental Asthma. At
sacrifice, broncho-alveolar lavage (BAL) was performed and total BAL leukocytes counted (A)
and BAL cellular differentials determined using May-Grunwald Giemsa stain (B). Typical BAL cell
count in a naïve animal, not exposed to HDM, is represented by a dotted line at 150,000 in (A).
Total BAL eosinophils were then determined from these two assessments. Values in A and C
represent mean ± the SEM. n=8 per group. * p < 0.05, ** p < 0.01; a: p < 0.01, eosinophil percent
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in HDM vs HDM + Antibiotic Mix; b: p < 0.05, eosinophil percent in HDM + Amoxicillin vs HDM +
Antibiotic Mix.

Figure 14: Antibiotic Exposure Is Associated with Increased Disease
Pathology

Figure 14. Antibiotic Exposure Is Associated with Increased Disease Pathology. Formalin-fixed
slides were processed in a standard manner and stained with hematoxylin and eosin (top row, AC, 10X) or periodic acid-Schiff with hematoxylin counterstain (bottom row, D-F, 4X). Inflammation
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scores (G) and mucus scores (H) were determined in a blinded manner on a severity scale of 03. Data represent mean ± interquartile ranges. n=3 slides per group for HDM and HDM +
Antibiotic Mix, n=2 for HDM + Amoxicillin; five independent graders per slide. * p < 0.05, ** p <
0.01.

Figure 15: Antibiotic Exposure Is Associated with Heightened Serum
HDM-Specific IgE

Figure 15. Antibiotic Exposure Increases Serum HDM-Specific IgE Levels. At sacrifice, serum
was collected from animals exposed to HDM, HDM + Amoxicillin, and HDM + Antibiotic Mix.
HDM-specific IgE levels were determined by ELISA. Dual absorbance was calculated at 450 nm
and 570 nm over a range of serial dilutions. Data represent mean ± SEM values. Group
comparisons were made by Kruskal-Wallis test with Dunn’s multiple comparisons test on the area
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under the curves (AUC) of the samples. n=8 per group. a: p < 0.05, HDM + Antibiotic Mix vs
HDM.
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Figure 16: Antibiotic Exposure Significantly Increase Airway HyperReactivity
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Figure 16. Antibiotic Exposure Significantly Increase Airway Hyper-Reactivity. Mice underwent
tracheostomy and mechanical ventilation with the flexiVent system. Total respiratory system
resistance (Rrs) was measured following increasing doses of aerosolized methacholine (A). Rrs
was compared using Area Under the Curve (AUC) (B). Data represent mean ± SEM. n=4 for
HDM, n=9 for HDM + Antibiotic Mix. a: p < 0.05 for the interaction of antibiotic treatment status
and methacholine dose. * p < 0.05, HDM vs HDM + Antibiotic Mix AUC; ** p < 0.01, HDM vs
HDM + Antibiotic Mix for 300 mg/mL methacholine.

Figure 17: Antibiotic Exposure Reduces Regulatory Immune Cells in
the Lung-Draining (Hilar) Lymph Node (HLN)
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Figure 17. Antibiotic Exposure Reduces Regulatory Immune Cells in the Lung-Draining (Hilar)
Lymph Node (HLN). At sacrifice, HLNs were removed and cells isolated. These cells were
stained to identify CD3+CD4+Foxp3+ regulatory T cells (Tregs) and assessed by flow cytometry.
Error bars represent mean ± SEM. n=7 for HDM, n=8 for HDM + Amoxicillin and HDM + Antibiotic
Mix. * p < 0.05.

Figure 18: Antibiotic Exposure Reduces the Diversity of the Fecal
Microbiome

Figure 18. Antibiotic Exposure Reduces the Diversity of the Fecal Microbiome. Following 16S
rRNA sequencing, QIIME was used to analyze the sequence data and pick operational taxonomic
units (OTUs) against the GreenGenes database. OTUs present in the samples are represented
as bar graphs of the average percent of all organisms represented by each OTU in each group
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(A). In (A), o__ refers to Order, f__ refers to Family, and g__ refers to Genus. OTUs lacking a
lower classification (e.g. an organism identified at the Order level but not the Family or Genus
level) refers to an unidentified OTU within that level, not all organisms at that level. For example,
the OTU identified as Order Clostridales does not represent all Clostridales, merely one
Clostridales at the 97% similarity level that is not classified in GreenGenes below the Order level.
Simpson’s Diversity Index for the fecal microbiome following HDM exposure was calculated (B)
and principal coordinates analysis (PCoA) of the unweighted UniFrac distances was performed
on samples before and after HDM exposure (C). n=8 for No Treatment and HDM + Antibiotic Mix,
n=5 for HDM, n=6 for Antibiotic Mix. ** p < 0.01.
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Figure 19: Antibiotic Exposure Results in Proportional Changes in
Multiple Taxa
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Figure 19. Antibiotic Exposure Results in Proportional Changes in Multiple Taxa.

Linear

Discriminant Analysis with Effect Size (LEfSe) was performed on the taxonomy table of
abundances for all taxa based on (A) antibiotic treatment as the class (either treated. ABX_Mix,
or not treated, No_Tx) and HDM exposure as the subclass (pre-exposure or post-exposure) or
(B) HDM exposure as the class (either exposed, HDM, or pre-exposure, PreHDM) and antibiotic
exposure as the subclass (treated or not treated). In (A) green bars represent taxa associated
with no antibiotic treatment (and not due to the effects of HDM exposure), and red bars represent
taxa associated with antibiotic treatment (and not due to the effects of HDM exposure). In (B)
blue bars represent taxa associated with HDM exposure (and not due to the effects of antibiotic
treatment). n=8 for No Treatment and HDM + Antibiotic Mix, n=5 for HDM, n=6 for Antibiotic Mix.
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Figure 20: Fecal Microbiome Diversity Directly Correlates with
Regulatory T Cell Proportions

Figure 20. Fecal Microbiome Diversity Directly Correlates with Regulatory T Cell Proportions.
Simpson’s Diversity Index plotted against the proportion of all CD4+ T Cells in the HLN that are
Foxp3+ Tregs. The Spearman r coefficient of correlation was calculated. The solid line is the
linear regression line plotted on the data, with the equation shown below the graph. The curved,
dotted lines represent the 95% confidence band for the linear regression line. n=5 for HDM, n=8
for HDM + Antibiotic Mix.
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CHAPTER 5
ANTIBIOTIC EXPOSURE DISRUPTS THE DEVELOPMENT OF
INHALATIONAL TOLERANCE
Introduction
A key objective of research endeavors aired at curing allergic asthma is restoration of
immunological tolerance to the offending allergen. Current asthma therapies that target the
immune system, such as corticosteroids and leukotriene inhibitors, broadly suppress immunity
but do not promote tolerance[4], and they carry a host of side effects ranging from infection risk
to reduced efficacy following repeated usage. Tolerance-promoting therapies would harness the
immune system to control itself, suppressing inappropriate inflammation while allowing beneficial
inflammatory responses, such as those to an invading pathogen, to proceed unimpeded[256].
Medical science has recognized that tolerance can be induced to foreign substances since the
early part of the 20th century. Work by Wells and Osborne in 1911 described oral tolerance, or
the process by which oral consumption of an allergen (for Wells and Osborne, ovalbumin
consumption by guinea pigs) produced a lasting and broad tolerance to that allergen, even if
exposed in an area other than the gut (such as application to the skin)[300; 301]. Others have
shown that this extends beyond ovalbumin (OVA) and that oral tolerance can be induced to
various pharmacologic compounds[302] as well as poison ivy extract[303]. The phenomenon has
long been recognized in human subjects, from an early case report at a Middle Eastern military
hospital of sulphanilamide desensitization in 1944[304] to modern efforts to promote tolerance to
food allergens such as peanut by carefully exposing allergic subjects to the offending protein or
protein(s)[253; 305].
As our understanding of oral tolerance grew, it became apparent that the microbiome was critical
for tolerance development. Experiments in the 1980s demonstrated that germ free (GF) mice
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either failed to develop oral tolerance or saw incomplete tolerance development the absence of a
host microbiome[306; 307]. Later studies have shown that the lack of a microbiome produces a
seemingly never-ending Th2 response, with no counteracting regulatory presence to reduce the
allergic reaction[149], and that this imbalance is at least in part due to a lack of T cells within the
gut-associated lymphoid tissue (GALT)[308]. This discovery reconnected us with work done
nearly seventy years prior, when Glimstedt’s 1936 assessments of GF guinea pigs revealed that
that Peyer’s patches, an important component of GALT, are fewer in number and that gutassociated lymph nodes have disorganized architecture[309], findings confirmed and expanded
upon in laboratory mice decades later[310]. Since then, a host of research has demonstrated
that a healthy microbiome is absolutely required for proper immune development and function,
and that disruption of the microbiome can produce lasting immunological consequences, including
for tolerance development[123].
While we know much of the interactions between the microbiome and the host which power oral
tolerance, much less is known about the importance of the microbiome for the development of
inhalational tolerance. A growing body of work has shown that disruption of the microbiome,
particularly following antibiotic (ABX) exposure, increases the severity of or susceptibility to AAD
in animal models[117; 118] and asthma in human subjects[112–116]. These studies have yielded
important insights into disease pathogenesis, but revealed little about the effect of the microbiome
on inhalational tolerance development. One recent study delved a little deeper into this area,
exploring the relationship of the lung microbiome to the development of tolerance to HDM. This
report suggested that lung microbiota, acting through the receptor PD-L1, provide protection
against allergic inflammation, but it did not evaluate true tolerance, as the exposure period for
HDM was only three weeks and the group did not see eosinophilia resolve even in control
animals[133].

As we have shown, tolerance to inhaled allergens including OVA[257] and

HDM[32] requires many weeks of continuous exposure (six and eleven, respectively).
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In the present chapter, we undertook investigation of the effect of ABX administration on the
development of inhalational tolerance. Based on prior results concerning AAD severity and the
existing body of oral tolerance literature, we hypothesized that disruption of the microbiome using
ABX would impair the development of inhalational tolerance and lead failure to suppress
symptoms of AAD. The following experiments will explore this hypothesis using three ABX
exposure models.

Results
Tylosin and Amoxicillin Do Not Impair the Development of Inhalational
Tolerance
Animals were first exposed to a combination of amoxicillin and tylosin and HDM (HDM + Antibiotic
Pair) or HDM alone in the manner of Nobel and colleagues[228], receiving exposure to ABX
immediately after weaning. This ABX exposure protocol did not disrupt tolerance development
from the perspective of leukocytosis and eosinophilia (Figure 21). The relative eosinophilia in the
broncho-alveolar lavage (BAL) was not significantly different between HDM and HDM + Antibiotic
Pair mice (Figure 21A-B). Both HDM and HDM + Antibiotic Pair mice had similar eosinophilia at
eleven weeks (approximately 5% of BAL leukocytes or less) as has been previously reported for
eleven weeks of HDM exposure by our group[32]. BAL eosinophil numbers (Figure 21C) also did
not significantly differ between HDM and HDM + Antibiotic Pair mice. Overall leukocyte numbers
in the BAL (Figure 21D), lungs (Figure 21E), and lung-draining (hilar) lymph node (HLN, Figure
21F) also did not differ significantly between the two groups.

Tylosin and Amoxicillin Do Not Alter the Proportions of Foxp3+ Tregs in the
HLN or Lung
We[31; 32; 41] and others[30] have previously shown that regulatory T cells (Tregs) are key
mediators of the development of inhalational tolerance, particularly in the lung and lung96

associated lymphoid tissues. Examination of the HLN and lung of these mice for CD4+Foxp3+
Tregs did not show a difference between HDM and HDM + Antibiotic Pair mice (Figure 22A-B).
Both had percentages of Tregs in the HLN and lung that were approximately the same as those
seen in our previous study of the model[32].

Early-Life Exposure to Amoxicillin or a Mixture of Four Antibiotics Does Not
Impair the Development of Inhalational Tolerance
Mice were next exposed to a different ABX treatment protocol, the same one which significantly
increased the severity of AAD after five weeks of HDM exposure (refer to Chapter 3). These mice
received either HDM, HDM and amoxicillin (HDM + Amoxicillin), or HDM and a mixture of four
antibiotics (HDM + Antibiotic Mix). There were no significant differences in the relative (Figure
23A-B) or absolute (Figure 23C) numbers of eosinophils in the BAL between HDM, HDM +
Amoxicillin, and HDM + Antibiotic Mix animals. Furthermore, there were no significant differences
in the number of leukocytes in the BAL between the groups. Data for all groups were consistent
with previously reported results following eleven weeks of HDM exposure[32].

Lifelong Exposure to a Mixture of Four Antibiotics Impairs the Resolution of
Eosinophilia and the Development of Inhalational Tolerance to HDM
Mice were next subjected to an ABX exposure protocol adapted from the prior experiment as well
as the work of Russell and colleagues[229; 230]. Amoxicillin or Antibiotic Mix was administered
to mice beginning prior to birth (i.e. to pregnant mothers) and continued throughout life, including
during HDM exposure. Control mice were raised in an identical manner but did not receive ABX
of any kind. HDM + Antibiotic Mix resulted in sustained relative eosinophilia (Figure 24A-B) that
was significantly elevated above both HDM and HDM + Amoxicillin animals (with a mean
proportion of eosinophils of approximately 10% of all BAL leukocytes vs below 5% for HDM and
HDM + Amoxicillin). The absolute BAL eosinophilia was also significantly elevated in HDM +
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Antibiotic Mix mice, where the number of eosinophils was over ten-fold higher than in either HDM
or HDM + Amoxicillin mice (Figure 24C).
Furthermore, HDM + Antibiotic Mix animals had significantly higher total leukocyte counts in the
BAL and the lung as compared to both HDM and HDM + Amoxicillin animals (Figure 24D-E).
Indeed, leukocyte counts for HDM + Antibiotic Mix animals in both compartments were
approximately twice that seen for HDM animals. However, cell counts in the HLN did not differ
significantly between any of the three groups of animals.

Lifelong Exposure to a Mixture of Four Antibiotics Reduces the Proportions of
Tregs and Bregs in the HLN and Lung
In contrast to early-life exposure to tylosin and amoxicillin, HDM + Antibiotic Mix mice had
significantly lower proportions of CD4+Foxp3+ Tregs in the HLN (Figure 25A) as compared to
wither HDM or HDM + Amoxicillin mice. HDM + Antibiotic Mix mice had lower, although not
significantly so, proportions of Tregs in the lung (Figure 25C). As for Tregs after five weeks of
HDM (see Chapter 4), HDM + Amoxicillin animals fell between HDM and HDM + Antibiotic Mix
animals and did not significantly differ from either group.
In addition to Tregs, our lab has previously shown that regulatory B Cells (Bregs), which reside in
the CD5+ B Cell population, play an important role in the development of tolerance in experimental
asthma[41; 42]. HDM + Antibiotic Mix reduced the proportion of CD5+ B Cells in both the HLN
(Figure 25B) and the lung (Figure 25D) by approximately a quarter. HDM + Amoxicillin animals
again fell between HDM and HDM + Antibiotic Mix animals and did not significantly differ from
either.

Discussion
The present study provides the first evidence that disruption of the microbiome using ABX can
impair the development of inhalational tolerance. It was well-recognized that ABX could impair
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the development of oral tolerance[311; 312], and long recognized that the microbiome had a
general role in oral tolerance development[306; 307], but little was known of the effect of
microbiome disruption on tolerance in the lungs.
We note that different antibiotic regimens can have differing impacts on lung immunity. This idea
is perhaps unsurprising given current literature. Consider the case of Russell and colleagues and
their studies of neonatal antibiotic exposure. In one landmark study of neonatal ABX exposure,
they reported that vancomycin, but not streptomycin, increased the severity of experimental
asthma later in life[118]. Three years later, they reported that an identical treatment scheme had
the opposite effect in a different disease model, hypersensitivity pneumonitis, where streptomycin
produced worse disease while vancomycin had no effect on disease severity[230].
Absent evidence from Chapter 3 that oral tolerance does not develop to HDM, one might conclude
that lifelong ABX treatment impairs tolerance merely by disrupting oral tolerance, but that is clearly
not the case. Instead, these results lend support to the idea that tolerance to HDM is orchestrated
within the lung itself. The recent study linking the respiratory microbiome to PD-L1-mediated
tolerance in the lung may provide the most mechanistic clue[179]. While that study only examined
a short window of allergen administration (a maximum of three weeks), the present results
suggest that the lung microbome-PD-L1 axis may be relevant over the longer term.

One

interesting avenue to explore in future studies would be the evaluation of the PD-L1 axis with
lifelong ABX treatment. Some of the same deficiencies seen early in life in mice lacking a
microbiome could conceivably persist throughout life so long as ABX are being administered.
Assessment of the lung microbiome over this period would also be illuminating, although
limitations of assessment (i.e. animals must be sacrificed to sample the lung microbiome)
necessarily mean that it could not be monitored over time in the same animals as is the case for
the fecal microbiome.
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An important follow-up to this study is the assessment of the composition of the microbiome
following sustained ABX treatment. As we saw in Chapter 4, diversity of the fecal microbiome
directly correlates with the proportion of Tregs in the HLN. Given the similar relative lack of Tregs
seen here in mice exposed to ABX for their entire lives, a similar diversity-Treg relationship may
exist. Furthermore, it would also be interesting to determine if the organisms lost due to ABX
treatment are members of the groups known the induce Tregs, such as Clostridial fermenters and
B. fragilis. Their absence, would explain the dearth of Tregs seen with sustained ABX treatment,
particularly in light of evidence that iTregs induced in the gut can migrate to the lungs and
moderate allergic inflammation[35]. Evidence that gut Treg inducing microorganisms are down
would open the door to possible therapeutic interventions. While dietary fiber supplementation
might fail given ABX-depletion of the fermenters, perhaps direct supplementation with short-chain
fatty acids (SCFAs) would correct the deficit of Tregs seen with ABX therapy and resolve the
associated eosinophilia. A further possibility, albeit one with less clinical relevance, would be to
transfer iTregs into ABX-treated animals to see if supplementation with the missing cell population
could restrain allergic inflammation. Such studies have been performed in the absence of ABX
therapy[313; 314], but whether it can correct for changes induced by extended ABX therapy
remains to be determined. Similar experiments, perhaps to include experiments with concurrent
Treg transfer, could also be performed for CD5+ Bregs, as we have shown that transfer of such
cells is protective against allergic inflammation in an OVA mouse model of asthma[41]. If transfer
of either or both populations alleviated disease, it would strongly suggest that a population lost to
ABX treatment was responsible for the Breg/Treg induction, maintenance, or a combination
thereof.
A close examination of eosinophilia in mice exposed to lifelong ABX (Figure 24A-B) reveals a
bimodal distribution of samples, with three tightly clustered at around 12% of all BAL leukocytes
and two at approximately 5% or below. This distribution happened to mirror sex: the three animals
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with high eosinophilia were female (as were all samples in all other groups), while the two lower
samples were male. We had not previously noted sex differences in our HDM model[32], but
there is a growing recognition that sex can interact with the microbiome. Indeed, the sexmicrobiome axis has been termed by some the “microgenderome”[315]. Studies over the past
three years have suggested that the microbiome can impact autoimmunity[316; 317]; microbiome
metabolism and microbiome-diet interactions[318; 319]; and gastrointestinal immunity and
cytokine production[319]. With respect to the microbiome, sex may have an impact on how the
microbiome changes with time, including changes associated with circadian rhythm[320]. While
data are limited in human subjects, early reports suggest that there may be sex-specific
differences in the composition of the microbiome (including the vial microbiome) in humans,
although the clinical significance of differences reported remains almost completely
unknown[321–323]. Perhaps the microbiome response to long-term ABX therapy differs by sex,
and the males maintain a more robust and ABX-resistance microbiome when compared to the
females. Perhaps males retain a protective organism that is lacking in females. Or, perhaps
males lack a pro-inflammatory organism such as Proteobacteria[173] that female animals
possess. It is known that females experience more severe asthma than males[324], and it is
interesting to consider that this could arise from a difference in the underlying host
microgenderome.
A simple but important addition to this study is functional assessment. Eosinophilia is a key
definition of active disease in our models[32; 257], but few asthma sufferers worry about how
many eosinophils are patrolling their airways. Instead, the concern is with function, such as
wheeze and airway hyper-reactivity (AHR). While obtaining an accurate description of current
wheeze from a mouse remains a challenge as yet unsolved by neuroscientists, we do have means
to evaluate AHR[32]. It will be important to assess AHR after continuous ABX therapy and HDM
exposure to see if the persistent eosinophilia is coupled with decreased pulmonary function. If it
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is, that would also suggest that airway smooth muscle hypertrophy and hyperplasia is enhanced
or at the least made persistent by ABX therapy, a finding which could explain associations
between wheeze and ABX therapy in human subjects.
An important consideration concerning the ABX protocol utilized is one of clinical relevance.
Lifelong ABX therapy is not common in humans, nor is multi-ABX cocktail treatment of newborns
common. However, there is an exception to the latter that may have relevance for the present
study. Premature babies who experience sepsis, such as from necrotizing enterocolitis, require
extensive antibiotic therapy to survive. These children, when followed through development, tend
to have higher rates of asthma development[112]. Thus, while this model may be less relevant
for the typical childhood ABX exposure and subsequent asthma risk, it could have much relevance
for the septic neonate. An interesting test would be to only expose mice to ABX in the perinatal
period, perhaps ceasing at weaning, and assessing if tolerance development was disrupted. This
would be consistent with other groups who have also reported that neonatal and perinatal ABX
exposure, but not exposure later in life, increases the severity of AAD[118; 229].
To conclude, the present study demonstrates that development of inhalational tolerance is
dependent on an intact microbiome, and that disruption of the microbiome with ABX can impair
tolerance development. Furthermore, disruption of inhalational tolerance using ABX requires
exposure greater than simply at weaning, as was found to increase the severity of AAD in Chapter
4. However, just as ABX exposure early in life led to decreased lung-associated Tregs, so too
did continuous ABX exposure produce a relative dearth of Tregs that was associated with failure
to fully resolve eosinophilia. This loss of Tregs was accompanied by a relative deficit in CD5+ B
Cells, a population known to contain Bregs. Further study, including assessment of AHR and the
specific changes seen in the gut microbiome, will be required to begin to elucidate the
mechanisms connecting ABX exposure with sustained eosinophilia in the BAL and diminished
Tregs and Bregs in the HLN and lung.
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Figures
Figure 21: Early-life Amoxicillin and Tylosin Treatment Does Not
Impair the Development of Inhalational Tolerance
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Figure 21. Early-life Amoxicillin and Tylosin Treatment Does Not Impair the Development of
Inhalational Tolerance. BAL fluid was assessed for cellular populations using May-Grunwald stain
(A) and counted. From that, the proportion of eosinophils (B) was determined. The total number
of eosinophils (C), number of leukocytes in the BAL (D), number of leukocytes in the lung (E), and
number of leukocytes in the HLN (F) were also determined. Data in B-F represent the mean ±
the SEM. n=8 except for HDM HLN, where n=7. NS, not significant.

Figure 22: Amoxicillin and Tylosin Treatment Has No Effect on Treg
Populations

Figure 22. Amoxicillin and Tylosin Treatment Has No Effect on Treg Populations. Single-cell
suspensions of the HLN and Lung were stained with antibodies targeting CD3, CD4, and Foxp3
and assessed using flow cytometry. Regulatory T Cells (CD3+CD4+Foxp3+) were identified in
the HLN (A) and lung (B). Data represent the mean ± the SEM. n=8 HDM Lung Tregs, HDM +
Antibiotic Pair Tregs; n=7 HDM HLN Tregs, HDM + Antibiotic Pair Lung Tregs.
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Figure 23: Pulsed Amoxicillin or Antibiotic Mix Treatment Does Not
Impair the Development of Tolerance

Figure 23. Pulsed Amoxicillin Or Antibiotic Mix Treatment Does Not Impair the Development of
Tolerance. BAL fluid was assessed for cellular populations using May-Grunwald stain (A) and
counted. From that, the proportion of eosinophils (B) was determined. The total number of
eosinophils (C) and number of leukocytes in the BAL (D) were counted. Data in B-D represent
the mean ± the SEM. n=4 HDM; n=2 HDM + Amoxicillin; n=3 HDM + Antibiotic Mix.
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Figure 24: Continuous Antibiotic Exposure Prevents Resolution of
Eosinophilia and Leukocytosis
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Figure 24. Continuous Antibiotic Exposure Prevents Resolution of Eosinophilia and Leukocytosis.
BAL fluid was assessed for cellular populations using May-Grunwald stain (A) and counted. From
that, the proportion of eosinophils (B) was determined. The total number of eosinophils (C),
number of leukocytes/white blood cells (WBCs) in the BAL (D), number of leukocytes/WBCs in
the lung (E), and number of leukocytes/WBCs in the HLN (F) were also determined. Data in B-F
represent the mean ± the SEM. n=5 per group except for HDM + Antibiotic Mix HLN, where n=4.
a:p < 0.01, HDM + Antibiotic Mix vs HDM and HDM + Amoxicillin; * p < 0.05; ** p < 0.01; *** p <
0.001.
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Figure 25: Continuous Antibiotic Exposure Reduced Populations of
Regulatory T and B Cells

Figure 25. Continuous Antibiotic Exposure Reduced Populations of Regulatory T and B Cells.
Single-cell suspensions of the HLN and Lung were stained with antibodies targeting CD3, CD4,
CD5, CD19, B220, and Foxp3 and assessed using flow cytometry.

Regulatory T Cells

(CD3+CD4+Foxp3+) were identified in the HLN (A) and lung (C). Regulatory B Cells (CD3CD19+B220+CD5+) were identified in the HLN (B) and lung (D). Data represent the mean ± the
SEM. n=5 per group except for HDM + Antibiotic Mix HLN, where n=4. * p < 0.05; NS, not
significant.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
Innovation and Significance
The present body of work includes three important advances in our understanding of asthma and
its relationship to the microbiome. First, we show that the development of inhalational tolerance
to HDM is not a consequence of concurrent oral tolerance. Indeed, oral exposure to HDM not
only failed to induce tolerance but failed to produce any changes in the gut microbiome. Second,
we report that short, repeated ABX exposures early in life are sufficient to produce increased
severity of experimental asthma later in life. This finding is in contrast to other reports in the
literature which suggested that ABX exposure must either occur immediately following birth or be
accompanied by an additional insult (such as fungal inoculation) to produce increased severity of
disease. Third, we show that it is possible to disrupt the development of inhalational tolerance
through disruption of the microbiome using ABX. This is consistent with a large body of literature
concerning oral tolerance, where lack of microorganisms or ABX treatment can impair tolerance
development. Finally, for the latter two points we have also shown that increased severity of
experimental asthma and disruption of tolerance are associated with a loss of regulatory T cells
in the lung or lung-associated lymphatic tissue. This links the present work to the extensive
investigation of the role of Tregs in asthma undertaken by the Thrall laboratory since its first report
on inhalational tolerance in the late 1990s.
These findings, particularly the second, add much to our understanding of how the microbiome
influences asthma pathogenesis and provide tools for future studies of the same. Abundant
clinical evidence has linked early-life ABX exposure to increased risk of developing asthma, but
hitherto models of ABX exposure and asthma required exposures that had little relevance to those
seen in clinical medicine, such as many weeks of ABX exposure or exposure beginning prior to
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birth and continuing through early life. The model described in the present work, while by no
means perfect,

Future Directions and Concluding Discussion
The lab has long studied the mechanisms underlying asthma pathophysiology and those which
contribute to disease resolution and tolerance. However, the present work marks the first foray
of the lab into the contribution of the microbiome to both elements.

Accordingly, and

unsurprisingly for a PhD dissertation, these studies have seen far more stories begin than end.
In prior chapters, we have discussed the next steps for a number of the findings presented. Here,
we highlight a select few of the broader concepts that the present work has begun to uncover but
which await future efforts to fully elucidate.

How does the microbiome contribute to inhalational tolerance to HDM?
In the recent study of endotoxin in farm dust[180], the ability of dust to induce tolerance was
directly linked to endotoxin levels within the dust. Our data may suggest that, at the least, simple
endotoxin encounter is not the entire story.

HDM itself contains endotoxin[32], yet when

administered in the context of lifelong ABX it fails to produce complete tolerance and resolution
of disease. The presence of LPS can restore oral tolerance to OVA in GF mice[306], yet it is
unable to do so for inhalational tolerance in the face of ABX. This suggests that there is something
about a healthy microbial community early in life that is critical for the development of proper
immune responses in the lungs, as suggested by recent work examining the lung microbiome of
mice early in development[179].
Dissecting this relationship could be attempted using GF mice. By inoculating GF mice with
microbiome of varying composition, we could explore whether certain organisms are critical (as
suggested by recent clinical evidence[97]) or whether overall diversity of the microbiome is what
matters, as our data for ABX and AAD would indicate. It may be that endotoxin (perhaps through
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the A20 mechanisms indicated by Shuijis) is absolutely required for inhalational tolerance, but it
may simultaneously be true that the immune system is incapable of properly responding to
endotoxin in the absence of the microbiome at a critical time of immune maturation.

Can we undo the damage wrought by ABX?
We have shown in the present work that asthma can be made more severe through perturbation
of the microbiome. A natural question to follow these studies is if the reverse is possible. As
previously discussed, probiotics are not likely to prove effective in reversing the effects of ABX.
While they have shown great effect in mice, evidence remains decidedly mixed that they have
any beneficial effect in on humans asthma[189]. A better option is fecal microbiome transplant
(FMT), the only microbiome-based therapy with demonstrated clinical efficacy[190–192]. Using
the model described in Figure 6 of the Materials and Methods, we attempted to restore the
microbiome of ABX-exposed mice using donor feces from animals never exposed to ABX.
Foremost amongst the questions remaining is if the transplant we attempted was successful. 16S
analysis of the community following transplant will provide that answer. If the transplant was not
successful, that could explain why no effect was seen. However, if the transplant was successful,
that raises a second question: why was no protection seen? Here, the answer may lie in timing.
As discussed in the prior section of this chapter, the key concept of microbiome-immune
interactions is timing.

Microorganisms must be present at precisely the right moment in

development to provide the proper signals for health immune function[325]. It is possible that the
transplant strategy selected simply acts too late to have any benefit. A more appropriate strategy
may be to attempt to restore the microbiome using FMT immediately following each ABX
exposure (Figures 26 and 27). If we can prevent the ABX-induced loss of diversity that we have
linked to a loss of immune regulators, The childhood antibiotic course of the future may feature
an FMT pill as the final dose.
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How can we move beyond 16S?
16S rRNA sequencing is a useful tool to obtain a snapshot of the composition of the microbial
community, but it is limited in what it can teach us. If an organism is present, 16S sequencing
tells us nothing about what it is doing. Answering this question requires one or a combination of
three tools: metagenomics, metatranscriptomics, and metabolomics.
Metagenomics, or the study of all of the genes of all of the microorganisms within the microbiome,
is a snapshot of what could be expressed. Are genes associated with virulence present? Does
ABX exposure lead to a decrease in the relative proportion of genes related to fermentation of
dietary fiber and SCFA production? Such a change could suggest less SCFA production and less
microbiome-driven induction and maintenance of Tregs.
However, presence of genes does not guarantee expression.

One need only consider a

genetically female mammalian cell to realize this: two X chromosomes and their respective genes
are present, but only one is active in any given cell. Determination of active gene expression
requires assessment of RNA, and metatranscriptomics is the tool to do so for the microbiome.
Perhaps ABX treatment does not eliminate all organisms capable of inducing Tregs, but these
organisms may be expressing few to no genes associated with the metabolic products that
promote Treg formation. Perhaps a small population of organisms, and a correspondingly small
proportion of the total metagenome, are highly transcriptionally active. Metagenomics will not tell
you this, and 16S sequencing certainly will not.
The shortcoming of both metagenomics and metatranscriptomics is that they require some
knowledge of what you are looking for. One may discover that a certain bacterial gene is
abundant, or abundantly expressed, but if nothing is known of what that gene does (not an
uncommon situation when so many of the microorganisms we study have yet to even be cultured),
this tells us little of mechanism. Metabolomics is the next step, looking at metabolic products of
the microbial community. Are certain classes of lipids more or less abundant as tolerance
112

develops? Are byproducts of uric acid metabolism (potentially important for asthma, as discussed
in Chapter 1) accumulating following ABX therapy? Metabolomics can begin to answer these and
many similar questions.
Such efforts studies are critical to determine how the microbiome is affecting immunity in the
context of AAD and tolerance, particularly to identify pathways that we can target to promote
tolerance, erase the harmful effects of ABX, and end the asthma epidemic. To future students
will be the task of applying these new and rapidly-advancing analytical tools to the microbiomeasthma relationship.

Concluding Remarks
One of the most important lessons of this project was not scientific or mechanistic. That lesson
was that even a hypothesis which subsequently fails can inspire great insight if the studies to test
it are designed appropriately and if one always remembers to follow the data. The original
hypothesis guiding this work was that HDM exposure leads to the formation of a regulatory
microbiome and that this regulatory microbiome promotes the induction of Tregs and tolerance.
This hypothesis was clearly not sustained by the evidence gathered in the present work, but the
investigations to validate it were directly responsible for new insights into oral tolerance, the
effects of early-life ABX exposure, and the importance of the microbiome to inhalational tolerance
generation.
Despite recognition of the innumerable small actors inside of us 130 years ago[61], we still
understand so little of their importance to our health. Every new relationship we uncover between
the microbiome and the host immune system answers another vexing question (e.g. why did the
rise in allergic diseases seem to correlate with elimination of peptic ulcer disease?), but creates
many more. Such fields in science are the most exciting and the most promising, but also the
most challenging for even the accomplished investigator. What we have reported herein is only
the beginning of the story, and perhaps in another 130 years we will see ourselves near its end.
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Figures
Figure 26: Fecal Microbiome Transplant Following ABX Treatment
Does Not Protect Against Eosinophilia

Figure 26. Fecal Microbiome Transplant Following ABX Treatment Does Not Protect Against
Eosinophilia. BAL fluid was assessed for cellular populations using May-Grunwald stain (A) and
counted. From that, the proportion of eosinophils (B) was determined. n=4 per group.
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Figure 27: Alternative FMT Model Featuring Post-ABX Corrective
Dosing

Figure 27. Alternative FMT Model Featuring Post-ABX Corrective Dosing. Magenta arrows
indicate fecal gavage dates, occurring one day following the cessation of ABX therapy.
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APPENDIX
Appendix A: QIIME Analysis Script
#!/bin/bash
#PBS -l nodes=1:ppn=25
#PBS -N hpc1_27_mar_2016_hdm_pbs_2dplots
#PBS -V
# Number of processors to request.
you may kill a node
torque_procs=25

On HPC1, do not request more than 40 or

# Flag for processing multiplexed, single-index data
# Demultiplexed, dual-index data is assumed if the orig_files directory is
present
# Accepts 1 for yes and 0 for no
multiplexed=1
# References
reference_seqs=/home/CAM/aadami/references/gg_13_8_otus/rep_set/97_otus.fasta
# Script variables
data_source=/home/CAM/aadami/datasets
preprocess_directory=/home/CAM/aadami/analysis/2016-0324_hdm_pbs_analysis/preprocess
work_directory=/home/CAM/aadami/analysis/2016-03-24_hdm_pbs_analysis
split_libs_out=/home/CAM/aadami/analysis/2016-0324_hdm_pbs_analysis/split_libs_out
chimeric_seqs_out=/home/CAM/aadami/analysis/2016-0324_hdm_pbs_analysis/usearch_chimeras_out
otus_out=/home/CAM/aadami/analysis/2016-03-24_hdm_pbs_analysis/otus_out
map_file=/home/CAM/aadami/analysis/2016-03-24_hdm_pbs_analysis/merged_map.txt
map_file_2dclean=/home/CAM/aadami/analysis/2016-0324_hdm_pbs_analysis/merged_map_2dclean.txt
START=`date +%s`
# Modified from script provided by Kendra Maas of the University of
Connecticut Microbial Analysis, Resources, and Services (MARS) Facility and
from scripts referenced in Nelson et al 2015 PLoS ONE DOI:
10.1371/journal.pone.0094249
# Move into main analysis directory
cd $work_directory
# Clear the preprocessing directory of any content
# Remove any intermediate directories created by future steps
# This is useful only if you had a previous failed run and wish to retry it
# It will clear all existing work from previous runs in the working
directory!
rm -rf *.fna
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rm
rm
rm
rm

-rf
-rf
-rf
-rf

usearch_*
$preprocess_directory
$otus_out
$split_libs_out

# Actions for multiplexed data
if test $multiplexed -eq 1; then
# Combine samples from multiple runs (pre-MARS dual indexing) using only
the forward read
split_libraries_fastq.py -o $split_libs_out/ -i $data_source/201310_br_hdm_scd/*R1*.fastq,$data_source/201408_hdm_ova/*R1*.fastq,$data_source/2015-03_hdm_timecourse_gavage/*R1*.fastq b $data_source/2013-10_br_hdm_scd/*I1*.fastq,$data_source/201408_hdm_ova/*I1*.fastq,$data_source/2015-03_hdm_timecourse_gavage/*I1*.fastq m
$work_directory/R1_map.txt,$work_directory/R2_map.txt,$work_directory/R4_map.
txt -q 19
fi
# Actions for demultiplexed data
if test -d orig_files; then
# Make and move into the preprocessing directory, copying all original
files to it
mkdir $preprocess_directory
cp -rf orig_files/* $preprocess_directory/
cd $preprocess_directory
# Loop through data folders and move files, renaming them by sample
mkdir $preprocess_directory/fastq
for i in */Data/Intensities/BaseCalls/*.gz; do mv $i "fastq""/"${i%%*}"."`basename $i`; done
# Merge all paired ends by sample
mkdir qiime
multiple_join_paired_ends.py -i . -o $preprocess_directory/qiime/
# Remove any fastq files that failed to join
mkdir nonjoin
find qiime/ -name "fastqjoin.un*" -print -exec mv {} nonjoin/ \;
find qiime/ -size "0" -print -exec mv {} nonjoin/ \;
# Merge all demultiplexed libraries by sampleID using filenames,
retaining only QScores above 19
multiple_split_libraries_fastq.py -i $preprocess_directory/qiime/ -o
$preprocess_directory/qiime/ --demultiplexing_method sampleid_by_file -include_input_dir_path -p $work_directory/qiime_parameters.txt
# Remove extra BaseSpace info from sequence names in seqs.fna
cp $preprocess_directory/qiime/seqs.fna
$preprocess_directory/qiime/demultiplexed_with_basespace_info_seqs.fna
sed 's/_S.*_L001.*join.fastq//g'
$preprocess_directory/qiime/demultiplexed_with_basespace_info_seqs.fna >
$preprocess_directory/qiime/basespace_cleaned_seqs.fna
# Count sequences: what did we get?
echo "Sequences after demultiplexing\n"
count_seqs.py -i $preprocess_directory/qiime/basespace_cleaned_seqs.fna
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# Move into main analysis directory
cd $work_directory
# Concatenate the two fasta files
cp $preprocess_directory/qiime/basespace_cleaned_seqs.fna .
cat $split_libs_out/seqs.fna >> basespace_cleaned_seqs.fna
# Count sequences: what did we get?
echo "Sequences after concatenation\n"
count_seqs.py -i basespace_cleaned_seqs.fna
fi
# Length filter sequences to between 245 and 260 bp
# This command
# 1) checks to see if the current line begins with a fasta sequence
identifier, which always starts with >. In other words, says if the
beginning of the line (^) is NOT (!) followed by >
# 2) stops all activity and moves to the next line
# 3) if it passes 1 and 2, grabs the current line and copies it into the
variable seq
# 4) asks if the length of seq is between 245 and 260 bp inclusive, and
finally 5) prints a newline and then the contents of seq if the line met the
length conditions.
# Note that this will fail to generate the expected output if your input
FASTA file has sequences that are not represented on a single line!
awk '!/^>/ { next } { getline seq } (length(seq) >= 245 && length(seq) <=
260) { print $0 "\n" seq }' basespace_cleaned_seqs.fna >
length_filtered_seqs.fna
# Count sequences: what did we get?
echo "Sequences after length filtering\n"
count_seqs.py -i length_filtered_seqs.fna
# Check for chimeric sequences using usearch61
identify_chimeric_seqs.py -i length_filtered_seqs.fna -m usearch61 -o
$chimeric_seqs_out/ -r $reference_seqs
filter_fasta.py -f length_filtered_seqs.fna -o seqs_chimeras_filtered.fna -s
$chimeric_seqs_out/chimeras.txt -n
# Count sequences: what did we get?
echo "Sequences after chimera checking\n"
count_seqs.py -i seqs_chimeras_filtered.fna
# Pick OTUs using usearch61 in an open reference manner (i.e. reference based
and then de novo on unmatched sequences)
pick_open_reference_otus.py -o $otus_out/ -i seqs_chimeras_filtered.fna -r
$reference_seqs -m usearch61 -a -O $torque_procs
# Summarize OTU table information (i.e. how many sequences do we have for
each sample)
biom summarize-table -i $otus_out/otu_table_mc2_w_tax_no_pynast_failures.biom
-o $otus_out/otu_table_mc2_w_tax_no_pynast_failures_summary.txt
# Calculate alpha and beta diversity metrics (metrics specified in parameters
file), rarefying to 10000 reads
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core_diversity_analyses.py -o $otus_out/diversity/ -i
$otus_out/otu_table_mc2_w_tax_no_pynast_failures.biom -m $map_file -t
$otus_out/rep_set.tre -p $work_directory/qiime_parameters.txt -e 10000 -c
"Timepoint,TimepointExtra,GroupTimepoint" -a -O $torque_procs
# Calculate alpha and beta diversity metrics (metrics specified in parameters
file), rarefying to 5000 reads
core_diversity_analyses.py -o $otus_out/diversity5k/ -i
$otus_out/otu_table_mc2_w_tax_no_pynast_failures.biom -m $map_file -t
$otus_out/rep_set.tre -p $work_directory/qiime_parameters.txt -e 5000 -c
"Timepoint,TimepointExtra,GroupTimepoint" -a -O $torque_procs
# Set mapfile and preference variables
map_file_2dclean=/home/CAM/aadami/analysis/2016-0324_hdm_pbs_analysis/merged_map_2dclean.txt
map_file_gp35=/home/CAM/aadami/analysis/2016-0324_hdm_pbs_analysis/merged_map_gp35.txt
map_file_gp27=/home/CAM/aadami/analysis/2016-0324_hdm_pbs_analysis/merged_map_gp27.txt
map_file_gp06=/home/CAM/aadami/analysis/2016-0324_hdm_pbs_analysis/merged_map_gp06.txt
plot_prefs=/home/CAM/aadami/analysis/2016-0324_hdm_pbs_analysis/plot_prefs.txt
twodplots_out=/home/CAM/aadami/analysis/2016-0324_hdm_pbs_analysis/otus_out/diversity/2dplots
# Make plots
make_2d_plots.py -i
$otus_out/diversity/bdiv_even10000/unweighted_unifrac_pc.txt -m $map_file -b
'Timepoint' -o $twodplots_out/TE/ -p $plot_prefs
make_2d_plots.py -i
$otus_out/diversity/bdiv_even10000/unweighted_unifrac_pc.txt -m
$map_file_2dclean -b 'Timepoint' -o $twodplots_out/TE_clean/ -p $plot_prefs
make_2d_plots.py -i
$otus_out/diversity/bdiv_even10000/unweighted_unifrac_pc.txt -m
$map_file_gp35 -b 'Timepoint' -o $twodplots_out/TE_gp35/ -p $plot_prefs
make_2d_plots.py -i
$otus_out/diversity/bdiv_even10000/unweighted_unifrac_pc.txt -m
$map_file_gp27 -b 'Timepoint' -o $twodplots_out/TE_gp27/ -p $plot_prefs
make_2d_plots.py -i
$otus_out/diversity/bdiv_even10000/unweighted_unifrac_pc.txt -m
$map_file_gp06 -b 'Timepoint' -o $twodplots_out/TE_gp06/ -p $plot_prefs
# End script
echo ''
END=`date +%s`
RUNTIME=$(( END - START ))
echo "This job took $RUNTIME seconds to complete"
echo "Began "
date -d @$START
echo "\n"
echo "Ended "
date -d @$END
exit
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Appendix B: QIIME Settings
split_libraries_fastq:phred_quality_threshold 19
alpha_diversity:metrics PD_whole_tree,chao1,observed_otus,shannon,simpson
beta_diversity:metrics
bray_curtis,binary_ochiai,euclidean,unweighted_unifrac,weighted_unifrac

Appendix C: Oral Exposure to HDM Does Not Produce Inhalational
Tolerance
We have discussed the impact of inhaled HDM exposure on the gut microbiome and whether any
changes resulting therefrom may correlate with the development of tolerance (refer to Chapter 3).
It is well recognized that inhaled substances can be swallowed, and multiple groups have shown
that intranasal instillation of substances ranging from viruses to microspheres sees a proportion,
although not a majority, subsequently make its way to the gut[326–328]. To explore the possibility
that the generation of inhalational tolerance to HDM could be a product of oral tolerance due to
swallowed HDM, we gavaged mice in a manner identical to intranasal HDM exposure in terms of
timing and allergen delivery. We further sampled and assessed the gut microbome during the
course of gavage to assess for HDM-specific changes in the composition of the gut microbiome.
Refer to the Materials and Methods for a detailed description of the gavage procedure and timing.

Results
Eosinophilia but No Change in Leukocyte Numbers Accompany HDM Gavage
HDM gavage led to increased relative eosinophilia in the BAL as compared to PBS gavage (Figure
28A-B).

This eosinophilia was accompanied by a relative decrease in the proportion of

macrophages in HDM-gavaged animals as compared to PBS-gavaged animals (Figure 28A).
Absolute numbers of eosinophils did not differ between the groups (Figure 28C).

BAL

leukocytosis was significantly elevated in HDM-gavaged animals as compared to PBS-gavaged
120

animals, although this difference was primarily driven by a single sample (Figure 28D). Cell
counts in the HLN (Figure 28E) and the lung (Figure 28F) did not differ significantly between
treatment groups.

Eleven Weeks of HDM Gavage Does Not Induce Oral Tolerance
Following eleven weeks of HDM or PBS gavage, both groups of animals were subjected to two
weeks of intranasal HDM exposure to induce AAD. Robust AAD was induced in both treatment
groups, with over 50% of airway leukocytes being eosinophils (Figure 29A-B). These proportions
are similar to expected values we have previously published in the model[32]. Similarly, the
absolute number of eosinophils did not differ between the animals which had received HDM
gavage and those which had received PBS gavage (Figure 29C). Furthermore, neither BAL
(Figure 29D), lung (Figure 29E), nor HLN (Figure 29F) leukocyte counts differed significantly
between the two treatment groups. Overall, the type of gavage received did not appreciably
change AAD cellular profiles.

The Fecal Microbiome of HDM-Gavaged Animals Does Not Differ from that of PBSGavaged Animals
Fecal samples obtained from animals over the course of gavage and subsequent intranasal HDM
were evaluated using QIIME. During the course of gavage, the community composition shifted in
a similar manner between PBS- and HDM-gavaged animals (Figure 30A).

The relative

abundance of a group of unclassified organisms of family Rikenellaceae increased, as did the
proportion of organisms of the genus Turicibacter. The relative abundance of genus Akkermansia
decreased from nearly a quarter of all naïve fecal organisms to less than 10% of all organisms.
Organisms of the genus Allobaculum first increased from less than 10% to nearly 20% of all
organisms before decreasing to 10% or less by eleven weeks of gavage.

121

However, while much of the community changes were mirrored between HDM- and PBS-gavaged
animals, one notable distinction did appear following two weeks of intranasal HDM. PBS gavage
and intranasal HDM saw a large increase in organisms of genus Prevotella. These organisms
were not absent from HDM gavaged and intranasal HDM animals, but the abundance in the latter
group was less than 10% as compared to over 15% for PBS gavage and HDM intranasal animals.
PCoA of the unweighted UniFrac distances reinforced the similarity between the two groups
(Figure 30B). Naïve samples began in the middle right of the principle coordinate plot, initially
moving to the lower left after five weeks of both HDM and PBS gavage but subsequently moving
to the upper left of the plot after both eleven weeks of HDM or PBS gavage and further intranasal
HDM exposure. As a result, the primary shift by the end of the experiment was along principle
coordinate 1. No distinct clustering was noted at any of the timepoints. This was reflected in the
proportion of the variation explained by principle coordinates 1 and 2, as neither one exceeded
15% of the total variation amongst the samples.
Finally, the similarity of the effects of the two treatments on the fecal microbiome was evident by
comparing the diversity of the fecal microbiome as gavage and intranasal HDM progressed
(Figure 30C). Neither sample significantly differed from the other at any timepoint, with both
tending to increase in diversity (as measured by Simpson’s diversity index) as time went on,
although comparison at most time points was hampered by a lack of samples (e.g. 2 and 5 week
gavage, 11 week gavage and HDM).

Discussion
The present study has two key results. First, these data demonstrate that HDM is distinct from
OVA and many other antigens in that oral tolerance does not develop in response to exposure to
HDM, at least not at the same timescale as it does when inhaled. Second, these results suggest
that the inhalational tolerance which develops in response to sustained, inhalational
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administration of HDM is not an unintentional byproduct of oral tolerance, as oral tolerance was
unable to be induced following eleven weeks of oral exposure.
While we initially suspected that changes we saw in some groups exposed to inhaled house dust
mite were due to the interaction of the gut microbiome with swallowed HDM, the present study
tends to suggest this is not the case. Indeed, the similarity of animals gavaged or exposed
intranasally to HDM or PBS was striking, with the same dominating taxa (unidentified order
Clostridales, Bacteroides family S24-7, and genus Akkermansia) present in all groups. At the
least, this suggests that any differential changes in the gut microbiome due to HDM exposure are
due less to swallowing of inhaled allergen and perhaps more to the interaction of the diseased
lung with the gut (a relationship which has been defined by others as the gut-lung axis[329; 330])
and vice-versa.
A surprising finding from the gavage experiments was the complete failure of oral tolerance
development. Both HDM- and PBS-gavaged animals had eosinophilia of expected severity
following two weeks of HDM intranasal exposure, appearing as if the eleven weeks of gavage
had no effect at all on the response to HDM. This is in sharp contrast to OVA, where oral tolerance
is robust and consistently-inducible. Indeed, oral tolerance to OVA completely abrogates or highly
attenuates disease on subsequent inhalational exposure[331; 332]. This difference is in spite of
both antigens being capable of producing inhalational tolerance[32; 257], suggesting that the
mechanisms mediating tolerance may differ between the two. This idea may not be entirely
surprising. The two model allergens differ greatly in both composition and mode of disease
induction. OVA is a peptide, while HDM is an assortment of peptides, lipids, carbohydrates, and
other compounds derived from the dust mite and its associated microbial community. Inducing
AAD with OVA requires sensitization with OVA and an adjuvant (such as alum), while HDM can
induce AAD with no prior sensitization period.
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This and other differences could explain why so upwards of 80% of human asthmatics have
sensitivity to HDM[333; 334] and perhaps why oral tolerance fails for HDM. It also adds urgency
to the question of precisely how inhalational tolerance to HDM develops, as mechanisms therein
may provide a way to cure otherwise-intractable HDM-induced asthma. One recent mechanistic
study of a different kind of dust could provide clues, and brings the story back to the microbiome.
Schuijs and colleagues evaluated the means by which the farm environment can provide
protection against HDM-induced AAD[180]. Exposing mice to farm dust, the group found that
endotoxin in the dust promoted tolerance and non-reactivity of the pulmonary mucosal immune
system, acting through suppression of NF-κB signaling by the protein A20. The idea that LPS
and other bacterial products within dust could provide protection has much clinical evidence to
support it. Multiple investigations of house dust have shown that higher levels of endotoxin,
diversity of microorganisms, or some combination thereof within environmental dust (such as in
mattresses) correlates with protection from asthma[86; 88; 89; 92; 94; 96]. While the level of LPS
in the HDM extract utilized in the present study is low[32], it may be sufficient to induce a response
similar to that produced by the endotoxin in farm dust.
One interesting finding from the gavage experiments was the presence of eosinophilia in some,
but not all, HDM-gavaged animals following eleven weeks of gavage (unsurprisingly, no PBSgavaged animals displayed eosinophilia). Perhaps the most likely explanation for this is simple
aspiration of gavage materials by mice, inducing AAD in a similar manner to if the HDM had been
instilled intranasally. It is likely that such aspiration did not occur with each gavage exposure, or
it would conceivable have induced inhalational tolerance as if the HDM had been administered
directly to the lung compartment.
One of the few appreciable differences between the gavaged groups following intranasal HDM
was the presence of a sizable proportion of Prevotella in the PBS gavaged animals (over 15% of
all organisms in PBS Gavage + HDM as compared to 5% or less in HDM Gavage + HDM, Figure
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29A). Interestingly, among the few studies of the lung microbiome in humans, Prevotella has
been reported to be more abundant in control subjects than in asthmatics[173]. Furthermore, at
least one investigation has suggested that some Prevotella species may have anti-inflammatory
properties specifically in the context of lung inflammation[335].

It remains to be seen whether

this difference is a pure chance effect (such as one driven by cage differences, although with
multiple cages this is less likely) or a truly definitive characteristic of PBS gavage, but it clearly
has no effect on the early induction of AAD, as these animals have disease at least as severe as
HDM-gavaged animals.
To conclude, oral exposure to HDM in the same temporal manner as intranasal exposure does
not induce oral tolerance to HDM and subsequent protection against AAD, in contrast to the robust
oral tolerance seen with OVA. With respect to the gut microbiome, few changes are seen between
HDM and PBS gavage save for an increase in the proportion of Prevotella in HDM-gavaged mice,
the significance of which (if any) remains unclear. Much remains to be explored with respect to
HDM gavage. Perhaps the amount of HDM gavaged is too high, and a smaller amount would
have led to tolerance (e.g. equivalent to how much may be swallowed when it is instilled
intranasally). Furthermore, we do not know if the lack of tolerance is simply in the lung or
systemic, as HDM gavage could conceivably be protective against exposure to HDM elsewhere
(e.g. footpad). These questions await future investigation and investigators to answer.
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Figures

Figure 28: 11 Weeks of HDM Gavage Produces Slight Eosinophilia

Figure 28. 11 Weeks of HDM Gavage Produces Slight Eosinophilia. BAL fluid was assessed for
cellular populations using May-Grunwald stain (A) and counted. From that, the proportion of
eosinophils (B) was determined. The total number of eosinophils (C), number of leukocytes in
the BAL (D), number of leukocytes in the HLN (E), and number of leukocytes in the lung were
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also determined. Data represent two independent experiments, n=10 per group except for PBS
Gavage HLN cell counts, where n=9. a: p < 0.05, Eosinophil %, HDM Gavage vs PBS Gavage;
b: p < 0.05, Macrophage %, HDM Gavage vs PBS Gavage; * p < 0.05.

Figure 29: 11 Weeks of HDM Gavage Is Not Protective Against
Subsequent Intranasal HDM Exposure
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Figure 29. 11 Weeks of HDM Gavage Is Not Protective Against Subsequent Intranasal HDM
Exposure. BAL fluid was assessed for cellular populations using May-Grunwald stain (A) and
counted. From that, the proportion of eosinophils (B) was determined. The total number of
eosinophils (C), number of leukocytes in the BAL (D), number of leukocytes in the HLN (E), and
number of leukocytes in the lung were also determined. Data in B-F represent the mean ± the
SEM. Data represent two independent experiments, n=10 per group except for HDM Gavage +
HDM Differentials, Eosinophil %, Eosinophil Counts, and HLN cell counts, where n=9.
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Figure 30: HDM Gavage Produces No Change in the Composition of
the Fecal Microbiome

Figure 30. HDM Gavage Produces No Change in the Composition of the Fecal Microbiome.
QIIME was used to pick OTUs and analyze samples from mice that had received PBS or HDM
gavage. OTUs picked at the 97% similarity level are represented as bars in (A). Bars represent
the average abundance of each OTU. In (A), o__ refers to Order, f__ refers to Family, and g__
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refers to Genus. OTUs lacking a lower classification (e.g. an organism identified at the Order
level but not the Family or Genus level) refers to an unidentified OTU within that level, not all
organisms at that level. For example, the OTU identified as Order Clostridales does not represent
all Clostridales, merely one Clostridales at the 97% similarity level that is not classified in
GreenGenes below the Order level.

PCoA was performed on the distance matrix of the

unweighted UniFrac distances and the two largest principal coordinates represented (B).
Simpson’s diversity index was calculated for each sample and plotted (C). Data in (C) represent
the mean ± the SEM except where no error bars are present. If error bars are not present, that
point represents a single sample. The addition of “+ HDM” indicates two weeks of intranasal HDM
exposure following the specified gavage (PBS or HDM). n=9, Naïve; n=5, 2 Week HDM Gavage;
n=6, 2 Week PBS Gavage; n=1, 5 Week HDM Gavage; n=6, 5 Week PBS Gavage; n=3, 11 Week
HDM Gavage; n=3, 11 Week PBS Gavage; n=1, 11 Week HDM Gavage + HDM; n=1, 11 Week
PBS Gavage + HDM.
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